assessment_number;brand_name;active_substance;disease_area;indication;gba_procedure_start_date;gba_first_resolution_date;gba_current_resolution_date;bundled_assessment;undergone_reevaluation;indication_label;subpopulation;patient_population_min;patient_population_max;patient_population_avg;appropriate_comparative_therapy;additional_benefit;applicant_company;assessment_status;full_assessment_status;assessment_type;gba_orphan_drug_status_during_evaluation;therapeutic_area;additional_benefit_best_subpopulation;endpoints;study_design;procedure_number;study_comparator
523;Cyramza;ramucirumab;Non-small cell lung cancer (NSCLC);Non-small cell lung cancer, EGFR mutation, first-line;2020-02-15;2020-08-20;2020-08-20;No;No;Cyramza is indicated in combination with erlotinib for the first-line treatment of adult patients with metastatic non-small cell lung cancer with activating epidermal growth factor receptor (EGFR) mutations.;"b) Adult patients with metastatic NSCLC with activating EGFR mutations other than L858R or del 19; first-line therapy";90.0;250.0;170.0;"Patient-specific therapy depending on the activating EGFR mutation with a choice of:
- afatinib, gefitinib, erlotinib, osimertinib
- cisplatin in combination with a third-generation cytostatic (vinorelbine or gemcitabine or docetaxel or paclitaxel or pemetrexed)
- carboplatin in combination with a third-generation cytostatic (vinorelbine or gemcitabine or docetaxel or paclitaxel or pemetrexed)
- carboplatin in combination with nab-paclitaxel
- monotherapy with gemcitabine or vinorelbine (only for patients with ECOG performance status 2 as an alternative to platinum-based combination treatment).";No additional benefit;Lilly Deutschland GmbH;Valid;Valid;New application area;No;Oncology;No additional benefit;Progression-free survival, Overall survival, Objective response rate, Disease control rate, Duration of response, EQ-5D VAS, Lung Cancer Symptom Scale, Progression-free survival 2, Time to diagnosis of CNS metastases, Safety;"RELAY:  
Part A: Phase 1b, single-arm  
Part B: RCT Phase 3, double-blind, parallel  
Part C: Open, single-arm, exploratory, two-period";2020-02-15-D-515;"RELAY Part A:  
N/A

RELAY Part B:  
Placebo + Erlotinib

RELAY Part C:  
N/A"
799;Lumykras;sotorasib;Non-small cell lung cancer (NSCLC);Non-small cell lung cancer, KRAS G12C mutation, ≥ 1 previous therapy;2022-02-15;2022-08-04;2022-08-04;No;No;Lumykras is used as monotherapy for the treatment of adults with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation in whom progression has been observed after at least one previous systemic therapy.;b) Adults with advanced non-small cell lung cancer (NSCLC) with KRAS p.G12C mutation after first-line treatment with cytotoxic chemotherapy;60.0;130.0;105.0;"- Docetaxel (only for patients with PD-L1 negative tumors) or
- pemetrexed (only for patients with PD-L1 negative tumors and except for predominantly squamous cell histology) or
- nivolumab or
- pembrolizumab (only for patients with PD-L1 expressing tumors (PD-L1 expression ≥ 1% of tumor cells)) or
- atezolizumab or
- docetaxel in combination with nintedanib (only for patients with PD-L1 negative tumors and adenocarcinoma histology)";No additional benefit;Amgen Europe B.V.;Changed;Changed;First indication;No;Oncology;No additional benefit;;;2022-02-15-D-787;
783;Rybrevant;amivantamab;Non-small cell lung cancer (NSCLC);Lung cancer, non-small cell, EGFR exon 20 insertion mutation, after platinum-based therapy;2022-01-15;2022-07-07;2022-07-07;No;No;Rybrevant as monotherapy is indicated for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) and activating exon 20 insertion mutations of the epidermal growth factor receptor (EGFR) after failure of platinum-based therapy.;a) Adults with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) exon 20 insertion mutations after failure of platinum-based chemotherapy for whom further chemotherapy is indicated;8.0;22.0;15.0;"- Docetaxel or
- docetaxel in combination with nintedanib or
- pemetrexed";No additional benefit;Janssen-Cilag GmbH;Valid;Valid;First indication;No;Oncology;No additional benefit;Forced expiratory volume in 1 second, asthma symptoms, exacerbations, health-related quality of life, adverse events;"Study 1:
double-blind, parallel, RCT (Randomized Controlled Trial)";2022-01-015-D-788;"Study 1:  
Placebo"
807;Tepmetko;tepotinib;Non-small cell lung cancer (NSCLC);Non-small cell lung cancer, METex14 skipping, pre-treated patients;2022-03-01;2022-09-01;2022-09-01;No;No;Tepmetko is used in adult patients with advanced non-small cell lung cancer (NSCLC) with alterations leading to METex14 skipping (exon 14 skipping in the mesenchymal-epithelial transition factor gene) who require systemic therapy following platinum-based chemotherapy and/or immunotherapy.;c) Adults with advanced non-small cell lung cancer (NSCLC) with MET tyrosine kinase receptor exon 14 (METex14) skipping changes after first-line therapy with a PD-1/PD-L1 antibody in combination with platinum-containing chemotherapy or after sequential therapy with a PD-1/PD-L1 antibody and platinum-containing chemotherapy;400.0;680.0;540.0;Patient-specific therapy taking into account the previous therapy and histology with a choice of afatinib, pemetrexed, erlotinib, docetaxel, docetaxel in combination with ramucirumab and docetaxel in combination with nintedanib and vinorelbine.;No additional benefit;Merck Europe B.V.;Valid;Valid;First indication;No;Oncology;No additional benefit;Objective Response (IRC), Objective Response (Investigator), Duration of Response (IRC, Investigator), Objective Disease Control (IRC, Investigator), Progression-Free Survival (IRC, Investigator), Overall Survival, Patient-Reported Outcome: EQ-5D, EORTC QLQ-C30, EORTC QLQ-LC13, Safety and Tolerability: Adverse Events;"VISION:  
Single-arm, open-label, multicenter Phase II study";2022-03-01-D-781;As it is a single-arm study, no direct comparator is provided. The benefit assessment is therefore based on internal and historical comparison data.
1137;Tecentriq;atezolizumab;Non-small cell lung cancer (NSCLC);Non-small cell lung cancer, first-line;2024-10-01;2025-03-20;2025-03-20;No;No;Tecentriq as monotherapy is used in adult patients for the first-line treatment of advanced NSCLC who are unsuitable for platinum-based therapy.;"a) Adults with advanced NSCLC with PD-L1 expression ≥ 50% on tumor cells (TC) who are considered unsuitable for platinum-based therapy; first-line treatment";550.0;2190.0;1370.0;"− Pembrolizumab as monotherapy or
− cemiplimab as monotherapy";No additional benefit;Roche Pharma AG;Valid;Valid;New application area;No;Oncology;Minor additional benefit;Overall survival (OS), Overall survival rates at 6, 12, 18, and 24 months, ORR (investigator-assessed according to RECIST v1.1), PFS (investigator-assessed according to RECIST v1.1), DOR (investigator-assessed according to RECIST v1.1), OS and PFS (investigator-assessed) in patients with PD-L1 expression determined by the SP263 assay PRO, EORTC QLQ-C30, EORTC QLQ-LC13 tolerability endpoints, ORR, PFS, and DOR (investigator-assessed according to modified RECIST), DCR (investigator-assessed according to RECIST v1.1), EQ-5D-5L;"IPSOS:  
international, multicenter, open, parallel, Phase III, RCT (Randomized Controlled Trial)";2024-10-01-D-1112;"IPSOS:  
Monochemotherapy (Vinorelbine or Gemcitabine)"
547;Alunbrig;brigatinib;Non-small cell lung cancer (NSCLC);NSCLC, ALK+, ALK-inhibitor-naive patients;2020-05-01;2020-10-15;2020-10-15;No;No;Alunbrig is indicated as monotherapy in adult patients with anaplastic lymphoma kinase (ALK)-positive, advanced non-small cell lung cancer (NSCLC) who have not previously been treated with an ALK inhibitor.;b) Adult patients with anaplastic lymphoma kinase (ALK)-positive, advanced, non-small cell lung cancer without brain metastases who have not previously been treated with an ALK inhibitor;420.0;910.0;665.0;"- Crizotinib or
- alectinib";Minor additional benefit;Takeda GmbH;Valid;Valid;New application area;No;Oncology;Considerable additional benefit;Progression‐free survival assessed by BIRC, Tumor response assessed by BIRC (ORR, duration of response, time to response, disease control rate), Intracranial tumor response assessed by BIRC, Intracranial progression‐free survival assessed by BIRC, Overall survival, Safety and tolerability;ALTA-1L:  controlled, multicenter, open-label, parallel, Phase III study;2020-05-01-D-542;"ALTA-1L:  
Crizotinib"
523;Cyramza;ramucirumab;Non-small cell lung cancer (NSCLC);Non-small cell lung cancer, EGFR mutation, first-line;2020-02-15;2020-08-20;2020-08-20;No;No;Cyramza is indicated in combination with erlotinib for the first-line treatment of adult patients with metastatic non-small cell lung cancer with activating epidermal growth factor receptor (EGFR) mutations.;"a) Adult patients with metastatic NSCLC with the activating EGFR mutations L858R or del 19; first-line therapy";690.0;1560.0;1125.0;"- Afatinib or
- gefitinib or
- erlotinib or
- osimertinib";No additional benefit;Lilly Deutschland GmbH;Valid;Valid;New application area;No;Oncology;No additional benefit;Progression-free survival, Overall survival, Objective response rate, Disease control rate, Duration of response, EQ-5D VAS, Lung Cancer Symptom Scale, Progression-free survival 2, Time to diagnosis of CNS metastases, Safety;"RELAY:  
Part A: Phase 1b, single-arm  
Part B: RCT Phase 3, double-blind, parallel  
Part C: Open, single-arm, exploratory, two-period.";2020-02-15-D-515;"RELAY:  
Part A: N/A  
Part B: Placebo + Erlotinib  
Part C: N/A"
1134;Braftovi;encorafenib;Non-small cell lung cancer (NSCLC);Non-small cell lung cancer, advanced, BRAF V600E mutation, combination with binimetinib;2024-10-01;2025-03-20;2025-03-20;No;No;Encorafenib in combination with Binimetinib is used in adult patients with advanced non-small cell lung cancer (NSCLC) with a BRAF V600E mutation.;"c) Adults with advanced non-small cell lung cancer (NSCLC) with a BRAF V600E mutation; after first-line therapy";1.0;123.0;62.0;− Dabrafenib in combination with trametinib;No additional benefit;Pierre Fabre Pharma GmbH;Valid;Valid;New application area;No;Oncology;No additional benefit;;;2024-10-01-D-1114;
664;Retsevmo;selpercatinib;Non-small cell lung cancer (NSCLC);Non-small cell lung cancer, RET-fusion+, after platinum-based chemotherapy and/or immunotherapy;2021-03-15;2021-09-02;2021-09-02;No;No;"Retsevmo as monotherapy is used to treat adults with advanced RET fusion-positive non-small cell lung cancer (NSCLC) who require systemic therapy following platinum-based chemotherapy and/or treatment with immunotherapy.
Retsevmo as monotherapy is used to treat adults and adolescents aged 12 years and older with advanced RET-mutated medullary thyroid carcinoma (MTC) who require systemic therapy following treatment with cabozantinib and/or vandetanib.
Retsevmo as monotherapy is used to treat adults with advanced RET fusion-positive thyroid cancer who require systemic therapy following treatment with sorafenib and/or lenvatinib.";"b) Adults with RET fusion-positive advanced non-small cell lung cancer (NSCLC) for whom systemic therapy is indicated; after first-line treatment with cytotoxic chemotherapy";20.0;80.0;50.0;"- Docetaxel (only for patients with PD-L1 negative tumors) or
- pemetrexed (only for patients with PD-L1 negative tumors and except for predominantly squamous cell histology) or
- nivolumab or
- pembrolizumab (only for patients with PD-L1 expressing tumors (TPS ≥ 1 %)) or
- atezolizumab or
- docetaxel in combination with nintedanib (only for patients with PD-L1 negative tumors and adenocarcinoma histology)";No additional benefit;Lilly Deutschland GmbH;Valid;Valid;First indication;No;Oncology;No additional benefit;Determination of the maximum tolerated dose (MTD) and the recommended phase 2 dose, Assessment of safety and tolerability, Characterization of the pharmacokinetic profile, Determination of the objective response rate, Determination of the objective response rate (confirmed by the IRC), Determination of the objective response rate (according to the investigator), Objective response rate in the central nervous system, Best overall response, Duration of response (overall and in the central nervous system), Time to response, Disease control rate, Progression-free survival, Overall survival, Safety and tolerability;"LIBRETTO-001:  
International, multicenter, open-label Phase 1/2 study conducted in two phases (dose escalation and dose expansion)";2021-03-15-D-655;Comparative therapy (ZVT): For advanced NSCLC with RET fusion, platinum-based chemotherapy and/or PD-1/PD-L1 inhibitors (as monotherapy or in combination) are typically used as standard treatment. These comparison groups serve as a reference for evaluating the added benefit of Selpercatinib in the corresponding subpopulations.
495;Tecentriq;atezolizumab;Non-small cell lung cancer (NSCLC);"NSCLC, non-squamous, first-line, combination with nab-paclitaxel and carboplatin; maintenance therapy";2019-10-01;2020-04-02;2020-04-02;No;No;Tecentriq is used in combination with nab-paclitaxel and carboplatin for the first-line treatment of metastatic NSCLC with non-squamous histology in adult patients who do not have EGFR mutations or ALK-positive NSCLC.;"b) Adult patients with metastatic non-small cell lung cancer with non-squamous cell histology and a Tumor Proportion Score [TPS] of < 50% (PD-L1 expression) and without EGFR- or ALK-positive tumor mutations; first-line therapy";5700.0;6480.0;6090.0;"- Cisplatin in combination with a third-generation cytostatic (vinorelbine or gemcitabine or docetaxel or paclitaxel or pemetrexed) or
- carboplatin in combination with a third-generation cytostatic (vinorelbine or gemcitabine or docetaxel or paclitaxel or pemetrexed) or
- carboplatin in combination with nab-paclitaxel or
- pembrolizumab in combination with pemetrexed and platinum chemotherapy";No additional benefit;Roche Pharma AG;Valid;Valid;New application area;No;Oncology;No additional benefit;Overall survival, Progression-free survival (RECIST v1.1), Objective response rate (RECIST v1.1), Duration of response (RECIST v1.1), EORTC QLQ-C30, EORTC QLQ-LC13, EQ-5D VAS, Adverse events;"IMpower130:
active-controlled, multicenter, open, parallel, Phase III, Randomized controlled trial (RCT)";2019-10-01-D-486;"IMpower130:  
Carboplatin + nab (Nanoparticle albumin bound)-Paclitaxel"
170;Giotrif;afatinib;Non-small cell lung cancer (NSCLC);Non-small cell lung cancer, EGFR mutation, EGFR-TKI-naïve patients;2015-05-15;2014-05-08;2015-11-05;No;Yes;GIOTRIF as monotherapy is used to treat EGFR-TKI-naïve adult patients with locally advanced and/or metastatic non-small cell lung cancer (NSCLC) with activating EGFR mutations.;1c) Non-pretreated patients with ECOG performance status 0 or 1. Patient group with other EGFR mutations;360.0;840.0;600.0;"- Gefitinib or erlotinib or
- cisplatin in combination with a third-generation cytostatic (vinorelbine or gemcitabine or docetaxel or paclitaxel or pemetrexed), taking into account the approval status, or
- carboplatin in combination with a third-generation cytostatic (only for patients with an increased risk of cisplatin-induced side effects in the context of combination therapy";No additional benefit;Boehringer Ingelheim Pharma GmbH & Co. KG;Valid;Valid;Reassessment: deadline expiration;No;Oncology;Major additional benefit;progression‑free survival, overall survival, objective response rate, symptomatology (EORTC QLQ‑C30, EORTC QLQ‑LC13), health‑related quality of life (EORTC QLQ‑C30, EQ‑5D), adverse events;"LUX-Lung 3 (NCT00949650):  
Randomized controlled trial (RCT), open, parallel, active controlled, Phase III study, multicenter (multinational).  

LUX-Lung 6 (NCT01121393):  
RCT, open, parallel, active controlled, Phase III study, multicenter (multinational).";2015-05-15-D-163;"LUX-Lung 3 (NCT00949650):  
Cisplatin + Pemetrexed  

LUX-Lung 6 (NCT01121393):  
Cisplatin + Gemcitabine"
224;Tagrisso;osimertinib;Non-small cell lung cancer (NSCLC);Non-small cell lung cancer, T790M-EGFR mutation;2016-03-15;2016-09-15;2016-09-15;No;No;TAGRISSO is indicated for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) and a positive epidermal growth factor receptor (EGFR) T790M mutation.;2) Treatment-naïve patients with a de novo positive T790M mutation;10.0;50.0;30.0;"Gefitinib or erlotinib or afatinib
(only for patients with activating EGFR mutations
 or
Patients with ECOG performance status 0, 1 or 2:
 − cisplatin in combination with a third-generation cytostatic agent (vinorelbine or gemcitabine or docetaxel or paclitaxel or pemetrexed) taking into account the approval
or
 − carboplatin in combination with a third-generation cytostatic drug (only for patients with an increased risk of cisplatin-induced side effects as part of combination therapy
Patients with ECOG performance status 2:
− alternative to platinum-based combination treatment: monotherapy with gemcitabine or vinorelbine";No additional benefit;AstraZeneca GmbH;Valid;Changed;First indication;No;Oncology;No additional benefit;FEV1, asthma symptoms, exacerbations, health-related quality of life, adverse events, morbidity, objective response rate (ORR), best overall response (BOR), progression-free survival (PFS), safety, AEs, SAEs, treatment discontinuations due to AEs, AEs with CTCAE grade ≥3, AEs with a frequency of ≥10%, exploratory endpoints, health-related quality of life and patient-reported symptoms, safety/tolerability, ORR, overall survival, progression-free survival, disease control rate, quality of life, symptomatology;"Study 1:  
Randomized Controlled Trial (RCT), double-blind, parallel";2016-03-15-D-219;"Study 1:  
Placebo"
664;Retsevmo;selpercatinib;Non-small cell lung cancer (NSCLC);Non-small cell lung cancer, RET-fusion+, after platinum-based chemotherapy and/or immunotherapy;2021-03-15;2021-09-02;2021-09-02;No;No;"Retsevmo as monotherapy is used to treat adults with advanced RET fusion-positive non-small cell lung cancer (NSCLC) who require systemic therapy following platinum-based chemotherapy and/or treatment with immunotherapy.
Retsevmo as monotherapy is used to treat adults and adolescents aged 12 years and older with advanced RET-mutated medullary thyroid carcinoma (MTC) who require systemic therapy following treatment with cabozantinib and/or vandetanib.
Retsevmo as monotherapy is used to treat adults with advanced RET fusion-positive thyroid cancer who require systemic therapy following treatment with sorafenib and/or lenvatinib.";"a) Adults with RET fusion-positive advanced non-small cell lung cancer (NSCLC) for whom systemic therapy is indicated; after first-line therapy with a PD-1/PD-L1 antibody as monotherapy";5.0;20.0;13.0;"- Cisplatin in combination with a third-generation cytostatic (vinorelbine or gemcitabine or docetaxel or paclitaxel or pemetrexed (except in the case of predominantly squamous histology)) or
- carboplatin in combination with a third-generation cytostatic agent (vinorelbine or gemcitabine or docetaxel or paclitaxel or pemetrexed (except in the case of predominantly squamous histology)) or
- carboplatin in combination with nab-paclitaxel or
- monotherapy with gemcitabine or vinorelbine (only for patients with ECOG performance status 2 as an alternative to platinum-based combination treatment)";No additional benefit;Lilly Deutschland GmbH;Valid;Valid;First indication;No;Oncology;No additional benefit;Determination of the maximum tolerated dose (MTD) and the recommended phase 2 dose, Assessment of safety and tolerability, Characterization of the pharmacokinetic profile, Determination of the objective response rate, Determination of the objective response rate (confirmed by the IRC), Determination of the objective response rate (according to the investigator), Objective response rate in the central nervous system, Best overall response, Duration of response (overall and in the central nervous system), Time to response, Disease control rate, Progression-free survival, Overall survival, Safety and tolerability;"LIBRETTO-001:
International, multicenter, open Phase 1/2 study conducted in two phases (dose escalation and dose expansion)";2021-03-15-D-655;LIBRETTO-001: Comparative therapy (ZVT): For advanced NSCLC with RET fusion, platinum-based chemotherapy and/or PD-1/PD-L1 inhibitors (either as monotherapy or in combination) are typically used as standard treatment. These comparison groups serve as a reference for assessing the added benefit of Selpercatinib in the appropriate subpopulations.
288;Mekinist;trametinib;Non-small cell lung cancer (NSCLC);Non-small cell lung cancer, BRAF V600 mutation;2017-05-01;2017-10-19;2017-10-19;No;No;Trametinib (Mekinist®) in combination with dabrafenib is indicated for the treatment of adult patients with advanced non-small cell lung cancer with a BRAF V600 mutation.;2b) Patients with previous treatment for whom therapy with docetaxel and pemetrexed is not indicated;80.0;350.0;215.0;Best supportive care (BSC);No additional benefit;Novartis Pharma GmbH;Valid;Valid;New application area;No;Oncology;No additional benefit;FEV1, asthma symptoms, exacerbations, health-related quality of life, adverse events;"Study 1:  
RCT (Randomized Controlled Trial), double-blind, parallel";2017-05-01-D-284;Study 1: Active comparative therapy: Platinum-based chemotherapy (e.g., cisplatin or carboplatin in combination with a third-generation cytostatic)
452;Keytruda;pembrolizumab;Non-small cell lung cancer (NSCLC);Non-small cell lung cancer, non-squamous cell histology, first-line, combination with pemetrexed and platinum chemotherapy;2019-04-01;2019-09-19;2019-09-19;No;No;KEYTRUDA is indicated in combination with pemetrexed and platinum chemotherapy for the first-line treatment of metastatic non-squamous NSCLC without EGFR- or ALK-positive tumor mutations in adults.;a) Adult patients with first-line treatment of metastatic non-squamous NSCLC without EGFR- or ALK-positive tumor mutations with a PD-L1 expression of < 50 % (TPS1);5700.0;6480.0;6090.0;"- Cisplatin in combination with a third-generation cytostatic (vinorelbine or gemcitabine or docetaxel or paclitaxel or pemetrexed) or
- carboplatin in combination with a third-generation cytostatic (vinorelbine or gemcitabine or docetaxel or paclitaxel or pemetrexed or
- carboplatin in combination with nab-paclitaxel";Non-quantifiable additional benefit;MSD Sharp & Dohme GmbH;Valid;Valid;New application area;No;Oncology;Non-quantifiable additional benefit;Overall survival, Progression-free survival, Objective response rate, Duration of response, Health-related quality of life and disease symptomatology measured by EORTC QLQ-C30, EORTC QLQ-LC13, and EQ-5D VAS, Adverse events;"KEYNOTE 021G:  
Phase II, Randomized, Active-Controlled, Multicenter, Open

KEYNOTE 189:  
Phase III, Randomized, Active-Controlled, Global, Multicenter, Double-Blind, Cross-Over[a]";2019-04-01-D-447;"KEYNOTE 021G:  
Platinum-based chemotherapy  

KEYNOTE 189:  
Placebo"
1135;Mektovi;binimetinib;Non-small cell lung cancer (NSCLC);Non-small cell lung cancer, advanced, BRAF V600E mutation, combination with encorafenib;2024-10-01;2025-03-20;2025-03-20;No;No;Binimetinib in combination with Encorafenib is used in adult patients with advanced non-small cell lung cancer (NSCLC) with a BRAF V600E mutation.;"a) Adults with advanced non-small cell lung cancer (NSCLC) with PD-L1 expression ≥ 50% and a BRAF V600E mutation; first-line therapy";31.0;102.0;67.0;"− Dabrafenib in combination with trametinib, or
− pembrolizumab as monotherapy, or
− atezolizumab as monotherapy, or
− cemiplimab as monotherapy, or
− nivolumab in combination with ipilimumab and 2 cycles of platinum-based chemotherapy (only for patients with ECOG PS 0–1), or
− pembrolizumab in combination with pemetrexed and platinum-based chemotherapy (only for patients with ECOG PS 0–1), or
− atezolizumab in combination with bevacizumab, paclitaxel, and carboplatin (only for patients with ECOG PS 0–1), or
− atezolizumab in combination with nab-paclitaxel and carboplatin (only for patients with ECOG PS 0–1), or
− cemiplimab in combination with platinum-based chemotherapy (only for patients with ECOG PS 0–1), or
− durvalumab in combination with tremelimumab and platinum-based chemotherapy (only for patients with ECOG PS 0–1).";No additional benefit;Pierre Fabre Pharma GmbH;Valid;Valid;New application area;No;Oncology;No additional benefit;;;2024-10-01-D-1113;
87;Giotrif;afatinib;Non-small cell lung cancer (NSCLC);Non-small cell lung cancer, EGFR mutation, EGFR-TKI-naïve patients;2013-11-15;2014-05-08;2014-05-08;No;No;Giotrif® as monotherapy is used for the treatment of EGFR-TKI-naive adult patients with locally advanced and/or metastatic non-small cell lung cancer (NSCLC) with activating EGFR mutations.;3) Patients pretreated with one or more chemotherapy(ies);40.0;170.0;105.0;Gefitinib or erlotinib;No additional benefit;Boehringer Ingelheim Pharma GmbH & Co. KG;Repealed;Repealed;First indication;No;Oncology;Considerable additional benefit;Progression-free survival, Overall Survival, Objective Response Rate, Symptomatology (EORTC QLQ-C30, EORTC QLQ-LC13), Health-related quality of life (EORTC QLQ-C30, EQ-5D), Adverse events;"LUX-Lung 3 (NCT00949650):  Randomized controlled trial (RCT), open-label, parallel, active-controlled, Phase III study, multicenter multinational

LUX-Lung 6 (NCT01121393):  Randomized controlled trial (RCT), open-label, parallel, active-controlled, Phase III study, multicenter multinational";2013-11-15-D-082;"NCT00949650:  
Cisplatin + Pemetrexed  

NCT01121393:  
Cisplatin + Gemcitabine"
1100;Alecensa;alectinib;Non-small cell lung cancer (NSCLC);Non-small cell lung cancer, ALK+, high risk of recurrence, adjuvant therapy;2024-07-15;2025-01-16;2025-01-16;No;No;Alecensa is used as monotherapy for the adjuvant treatment of adult patients with ALK-positive NSCLC at high risk of recurrence following complete tumor resection.;a) Adults with ALK-positive NSCLC at high risk of recurrence for adjuvant treatment after complete tumor resection, who are eligible for adjuvant platinum-based chemotherapy.;230.0;452.0;341.0;"Patient-specific postoperative (adjuvant) systemic chemotherapy with the selection of
- cisplatin in combination with vinorelbine, and
- cisplatin in combination with pemetrexed,
taking into account the patient’s general condition.";Major additional benefit;Roche Pharma AG;Valid;Valid;New application area;No;Oncology;Major additional benefit;"DFS (investigator-assessed), Overall Survival, DFS rates (after 3, 4, and 5 years), Localization of the first recurrence or a new primary NSCLC, CNS-DFS, PRO: SF-36v2 and EQ5D VAS, Pharmacokinetics, Biomarker, Adverse events; laboratory parameters, vital signs, ECG";"ALINA:  
Phase III; RCT (Randomized Controlled Trial), open, parallel, multicenter";2024-07-15-D-1079;"ALINA:  
Platinum-based chemotherapy"
1017;Enhertu;trastuzumab deruxtecan;Non-small cell lung cancer (NSCLC);Non-small cell lung cancer, HER2(ERBB2) mutation, pre-treated;2023-12-01;2024-05-16;2024-05-16;No;No;Enhertu is used as monotherapy for the treatment of adult patients with advanced NSCLC whose tumors have an activating HER2 (ERBB2) mutation and who require systemic therapy after platinum-based chemotherapy with or without immunotherapy.;a) Adults with advanced non-small cell lung cancer (NSCLC) whose tumors have an activating HER2 (ERBB2) mutation after prior treatment with platinum-containing chemotherapy without immunotherapy;9.0;25.0;17.0;"- Docetaxel (only for patients with PD-L1 negative tumors) or
- pemetrexed (only for patients with PD-L1 negative tumors and except in predominantly squamous histology) or
- nivolumab or
- pembrolizumab (only for patients with PD-L1 expressing tumors, Tumor Proportion Score (TPS) ≥ 1%) or
- atezolizumab or
- docetaxel in combination with nintedanib (only for patients with PD-L1 negative tumors and adenocarcinoma histology)";No additional benefit;Daiichi Sankyo Deutschland GmbH;Valid;Valid;New application area;No;Oncology;No additional benefit;ORR, assessed according to BICR, Confirmed ORR, assessed by the investigator, DOR, assessed according to BICR and by the investigator, DCR, PFS, Overall Survival, Quality of Life/PRO (EORTC QLQ-C30, EORTC QLQ-LC13), Safety, TTR;"DESTINY-Lung02:  
Randomized controlled trial (RCT), double-blind, parallel, multicenter, multinational, Phase II study";2023-12-01-D-990;"DESTINY-Lung02:  
Randomized clinical study with T‑DXd (Trastuzumab deruxtecan) as the product under assessment; no valid comparator available."
453;Keytruda;pembrolizumab;Non-small cell lung cancer (NSCLC);Non-small cell lung cancer, squamous cell histology, first-line, combination with carboplatin and (nab-) paclitaxel;2019-04-01;2019-09-19;2019-09-19;No;No;KEYTRUDA is indicated in combination with carboplatin and either paclitaxel or nab-paclitaxel for the first-line treatment of metastatic squamous NSCLC in adults.;b) Adult patients with first-line treatment of metastatic squamous NSCLC and PD-L1 expression of ≥ 50% (TPS1);1540.0;1610.0;1575.0;Pembrolizumab as monotherapy;No additional benefit;MSD Sharp & Dohme GmbH;Valid;Valid;New application area;No;Oncology;Considerable additional benefit;Overall Survival, Progression-Free Survival, Objective Response Rate, Duration of Response, Health-related Quality of Life and Symptomatology, Adverse Events;"KEYNOTE 407:  
Phase III randomized, active-controlled worldwide multicenter double-blind cross-over";2019-04-01-D-448;"KEYNOTE 407:  
Placebo, Carboplatin, Paclitaxel, nab-Paclitaxel"
186;Nivolumab BMS/Opdivo;nivolumab;Non-small cell lung cancer (NSCLC);Non-small cell lung carcinoma, squamous cell histology, after prior chemotherapy;2015-08-15;2016-02-04;2016-02-04;Yes;No;OPDIVO is indicated for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) with squamous cell histology after prior chemotherapy in adults.;1) Patients for whom treatment with docetaxel is indicated;3700.0;5200.0;4450.0;Docetaxel;Considerable additional benefit;Bristol-Myers Squibb GmbH & Co. KGaA;Valid;Valid;New application area;No;Oncology;Considerable additional benefit;Overall Survival (OS), Index value of disease-related symptoms according to LCSS, Health-related quality of life according to LCSS, Generic quality of life according to EQ-5D, Safety and tolerability (AEs);"CA209-017:  
open, parallel, RCT (Randomized Controlled Trial)";2015-08-15-D-184;"CA209-017:  
Docetaxel"
799;Lumykras;sotorasib;Non-small cell lung cancer (NSCLC);Non-small cell lung cancer, KRAS G12C mutation, ≥ 1 previous therapy;2022-02-15;2022-08-04;2022-08-04;No;No;Lumykras is used as monotherapy for the treatment of adults with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation in whom progression has been observed after at least one previous systemic therapy.;a) Adults with advanced non-small cell lung cancer (NSCLC) with KRAS p.G12C mutation after first-line therapy with a PD-1/PD-L1 antibody as monotherapy;80.0;170.0;125.0;"- Cisplatin in combination with a third-generation cytostatic (vinorelbine or gemcitabine or docetaxel or paclitaxel or pemetrexed (except in the case of predominantly squamous histology)) or
- carboplatin in combination with a third-generation cytostatic agent (vinorelbine or gemcitabine or docetaxel or paclitaxel or pemetrexed (except for predominantly squamous histology)) or
- carboplatin in combination with nab-paclitaxel or
- monotherapy with gemcitabine or vinorelbine (only for patients with ECOG performance status 2 as an alternative to platinum-based combination treatment)";No additional benefit;Amgen Europe B.V.;Valid;Changed;First indication;No;Oncology;No additional benefit;;;2022-02-15-D-787;
631;Opdivo;nivolumab;Non-small cell lung cancer (NSCLC);Non-small cell lung cancer, combination with ipilimumab and platinum-based chemotherapy, first-line;2020-12-15;2021-06-03;2021-06-03;No;No;Opdivo is indicated in combination with ipilimumab and 2 cycles of platinum-based chemotherapy for the first-line treatment of metastatic non-small cell lung cancer (NSCLC) in adults whose tumors do not have a sensitizing EGFR mutation or ALK translocation.;"b) Adult patients with metastatic non-small cell lung cancer (NSCLC) with a Tumor Proportion Score [TPS] of < 50% (PD-L1 expression) and without EGFR mutations or ALK translocations; first-line treatment";10630.0;11500.0;11065.0;"- Cisplatin in combination with a third-generation cytostatic (vinorelbine or gemcitabine or docetaxel or paclitaxel or pemetrexed (except in the case of predominantly squamous histology)) or
- carboplatin in combination with a third-generation cytostatic agent (vinorelbine or gemcitabine or docetaxel or paclitaxel or pemetrexed (except for predominantly squamous histology)) or
- carboplatin in combination with nab-paclitaxel or
- pembrolizumab in combination with pemetrexed and platinum-containing chemotherapy (only for patients with non-squamous histology) or
- pembrolizumab in combination with carboplatin and either paclitaxel or nab-paclitaxel (only for patients with squamous histology)";Minor additional benefit;Bristol-Myers Squibb Pharma EEIG;Valid;Valid;New application area;No;Oncology;Minor additional benefit;Overall Survival, Disease-related symptoms according to LCSS, Health-related quality of life according to LCSS, Health status according to EQ-5D-VAS, Adverse events;"CA209-9LA:  
Randomized controlled trial, open, parallel";2020-12-15-D-628;"CA209-9LA:  
Platinum-based chemotherapy"
694;Tecentriq;atezolizumab;Non-small cell lung cancer (NSCLC);Non-small cell lung cancer, PD-L1 expression ≥ 50 % on TC or ≥ 10 % on IC, EGFR/ALK-negative, first-line;2021-06-01;2021-11-19;2021-11-19;No;No;Tecentriq as monotherapy is used in adult patients for the first-line treatment of metastatic non-small cell lung cancer (NSCLC) whose tumors have PD-L1 expression ≥ 50% of tumor cells (tumor cells, TC) or ≥ 10 % in tumor-infiltrating immune cells (IC) and who do not have EGFR (epidermal growth factor receptor) mutations or ALK (anaplastic lymphoma kinase)-positive NSCLC.;"b) Adults with metastatic non-small cell lung cancer (NSCLC) whose tumors have PD-L1 expression < 50% of tumor cells and PD-L1 expression ≥ 10% in tumor-infiltrating immune cells and who do not have EGFR mutations or ALK-positive NSCLC; first line";580.0;650.0;615.0;"- Cisplatin in combination with a third-generation cytostatic (vinorelbine or gemcitabine or docetaxel or paclitaxel or pemetrexed (except in the case of predominantly squamous histology)) or
- carboplatin in combination with a third-generation cytostatic agent (vinorelbine or gemcitabine or docetaxel or paclitaxel or pemetrexed (except for predominantly squamous histology)) or
- carboplatin in combination with nab-paclitaxel or
- pembrolizumab in combination with pemetrexed and platinum-containing chemotherapy (only for adults with non-squamous histology) or
- pembrolizumab in combination with carboplatin and either paclitaxel or nab-paclitaxel (only for adults with squamous histology) or
- monotherapy with gemcitabine or vinorelbine (only for adults with ECOG performance status 2 as an alternative to platinum-based combination treatment)";No additional benefit;Roche Pharma AG;Valid;Valid;New application area;No;Oncology;No additional benefit;Overall Survival, Investigator-assessed PFS (RECIST v1.1), Investigator-assessed ORR (RECIST v1.1), Investigator-assessed DOR (RECIST v1.1), Investigator-assessed OS and PFS (RECIST v1.1) using SP263 IHC assay, OS rate at 1 and 2 years, Patient-reported outcomes (EORTC QLQ-C30 and EORTC QLQ-LC13), Adverse events, Immunogenicity, Investigator-assessed OS and PFS (RECIST v1.1) using 22C3 PD-L1 IHC assay, PFS rate at 6 months and 1 year, OS rate at 3 years, Subgroup analyses for investigator-assessed OS and PFS (RECIST v1.1), Health status assessed by EQ-5D-3L;"IMpower110:  
Phase III, Randomized controlled trial, open, active-controlled, parallel, multicenter";2021-06-01-D-671;"IMpower110:  
Platinum-based chemotherapy"
288;Mekinist;trametinib;Non-small cell lung cancer (NSCLC);Non-small cell lung cancer, BRAF V600 mutation;2017-05-01;2017-10-19;2017-10-19;No;No;Trametinib (Mekinist®) in combination with dabrafenib is indicated for the treatment of adult patients with advanced non-small cell lung cancer with a BRAF V600 mutation.;2a) Patients with previous treatment for whom therapy with docetaxel or pemetrexed is indicated;40.0;220.0;130.0;Docetaxel or pemetrexed;No additional benefit;Novartis Pharma GmbH;Valid;Valid;New application area;No;Oncology;No additional benefit;FEV1, asthma symptoms, exacerbations, health-related quality of life, adverse events;"Study 1:  
RCT (Randomized Controlled Trial), double-blind, parallel";2017-05-01-D-284;Study 1: Active comparative therapy: Platinum-based chemotherapy (e.g., cisplatin or carboplatin in combination with a third-generation cytostatic)
1026;Keytruda;pembrolizumab;Non-small cell lung cancer (NSCLC);Non-small cell lung carcinoma, adjuvant therapy, after prior chemotherapy;2024-05-01;2024-10-17;2024-10-17;No;No;Keytruda is indicated as a monotherapy for the adjuvant treatment of non-small cell lung cancer with a high risk of recurrence after complete resection and platinum-based chemotherapy in adults.;Adults with non-small cell lung cancer with a high risk of recurrence after complete resection and platinum-based chemotherapy - adjuvant treatment;2690.0;3200.0;2945.0;Observant waiting;No additional benefit;MSD Sharp & Dohme GmbH;Valid;Valid;New application area;No;Oncology;No additional benefit;Disease-Free Survival, Overall Survival, Side Effects, Disease Symptomatology and Health Status (Symptom scales EORTC QLQ-C30, EORTC QLQ-LC13 and EQ-5D VAS), Health-Related Quality of Life (Function Scales EORTC QLQ-C30);"KEYNOTE 091:  
Randomized, placebo-controlled, Phase III clinical study with parallel groups";2024-05-01-D-1058;"KEYNOTE 091:  
Placebo"
713;Tagrisso;osimertinib;Non-small cell lung cancer (NSCLC);Non-small cell lung cancer, EGFR mutations, adjuvant therapy;2021-07-01;2021-12-16;2021-12-16;No;No;TAGRISSO is indicated as monotherapy for adjuvant treatment after complete tumor resection in adult patients with stage IB-IIIA non-small cell lung cancer (NSCLC) whose tumors have mutations of the epidermal growth factor receptor (EGFR) as deletion in exon 19 or substitution mutation in exon 21 (L858R);b) Adults with stage IB-IIIA non-small cell lung cancer (NSCLC) with exon 19 deletion or exon 21 substitution (L858R) of the epidermal growth factor receptor (EGFR) for adjuvant treatment after complete tumor resection, after prior adjuvant platinum-based chemotherapy or who are not suitable for this.;640.0;930.0;785.0;Observational waiting;Non-quantifiable additional benefit;AstraZeneca GmbH;Valid;Valid;New application area;No;Oncology;Non-quantifiable additional benefit;disease‐free survival, overall survival, time to first subsequent therapy, time to second subsequent therapy, progression‐free survival, SF-36, adverse events;"ADAURA (D5164C00001):  
Randomized Controlled Trial (RCT), double-blind, parallel, crossover[a]";2021-07-01-D-701;"ADAURA (D5164C00001):  
Placebo"
44;Xalkori;crizotinib;Non-small cell lung cancer (NSCLC);Non-small cell lung cancer, ALK+, pre-treated patients;2012-11-15;2013-05-02;2013-05-02;No;No;XALKORI is used in adults for the treatment of pretreated anaplastic lymphoma kinase (ALK)-positive, advanced non-small cell lung cancer (NSCLC).;b) Patients for whom chemotherapy is not indicated.;140.0;140.0;140.0;Best supportive care (BSC) for the treatment of patients for whom chemotherapy is not indicated (this may particularly include patients with ECOG performance status 4, 3, and possibly 2).;No additional benefit;Pfizer Pharma GmbH;Repealed;Repealed;First indication;No;Oncology;Considerable additional benefit;Progression-Free Survival, Overall Survival, Objective Response Rate (ORR), Duration of Response (DR), Time to Response (TTR), Disease Control Rate (DCR), 6-Month Survival Probability, 1-Year Survival Probability, Adverse Events, Patient Reported Outcomes (PRO);"NCT00932893:  
RCT (Randomized Controlled Trial), open, multicenter, multinational, two-arm, Phase III, efficacy and safety study";2012-11-15-D-040;"NCT00932893:  
Pemetrexed, Docetaxel"
1129;Rybrevant;amivantamab;Non-small cell lung cancer (NSCLC);Non-small cell lung cancer (NSCLC), EGFR mutations, pre-treated, combination with carboplatin and pemetrexed;2025-02-01;2025-07-15;2025-07-15;No;No;;;;;;;;Janssen-Cilag GmbH;In progress;In progress;New application area;No;Oncology;;;;;
264;Zykadia;ceritinib;Non-small cell lung cancer (NSCLC);Non-small cell lung cancer, ALK+, after crizotinib pre-therapy;2016-10-01;2015-12-17;2017-03-16;No;Yes;Zykadia is used in adult patients for the treatment of advanced, anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) who have been pretreated with crizotinib.;1) Patients who are eligible for treatment with docetaxel or pemetrexed;100.0;450.0;275.0;Docetaxel or pemetrexed;Considerable additional benefit;Novartis Pharma GmbH;Valid;Valid;Reassessment: deadline expiration;No;Oncology;Considerable additional benefit;Progression-free survival, Overall survival, Tumor response (ORR, DCR, time to first response, duration of response), Intracranial tumor response (OIRR, IDCR, duration of intracranial response), Safety, Patient-reported outcomes: EORTC-QLQ-C30, EORTC-QLQ-LC13, LCSS, EQ-5D;"ASCEND-5:  
Randomized controlled Phase III study open parallel";2016-10-01-D-259;"ASCEND-5:  
Chemotherapy"
1096;Tagrisso;osimertinib;Non-small cell lung cancer (NSCLC);Non-small cell lung cancer, EGFR mutations, adjuvant therapy;2024-07-01;2021-12-16;2024-12-19;No;No;Tagrisso is indicated as monotherapy for the adjuvant treatment following complete tumor resection in adult patients with non-small cell lung cancer (NSCLC) at stages IB-IIIA, whose tumors exhibit epidermal growth factor receptor (EGFR) mutations, specifically a deletion in exon 19 or a substitution mutation in exon 21 (L858R).;b) Adults with NSCLC at stages IB-IIIA with an exon 19 deletion or exon 21 substitution (L858R) of the epidermal growth factor receptor (EGFR) for adjuvant treatment following complete tumor resection, after prior adjuvant platinum-based chemotherapy, or for those who are not suitable for such chemotherapy.;640.0;930.0;785.0;Watchful waiting;Major additional benefit;AstraZeneca GmbH;Valid;Valid;New application area;No;Oncology;Major additional benefit;Disease-free survival, Overall survival, Time to first subsequent therapy, SF-36, Adverse events;"ADAURA (D5164C00001):
crossover, double-blind, parallel, RCT (Randomized Controlled Trial)";2024-07-01-D-1077;"ADAURA (D5164C00001):  
Placebo"
464;Lorviqua;lorlatinib;Non-small cell lung cancer (NSCLC);Non-small cell lung cancer, ALK+, pre-treated patients;2019-06-01;2019-11-22;2019-11-22;No;No;"Lorviqua as monotherapy, is used to treat adult patients with anaplastic lymphoma kinase (ALK)-positive, advanced non-small cell lung cancer (NSCLC) whose disease has progressed after: Alectinib or ceritinib as first-line ALK tyrosine kinase inhibitor (TKI) therapy; or crizotinib and at least one other ALK TKI.";"b) Patients with ALK-positive, advanced NSCLC whose disease has progressed after alectinib or ceritinib as first ALK-TKI therapy or crizotinib and at least one other ALK-TKI; for whom further antineoplastic systemic therapy is not an option";40.0;250.0;145.0;Best supportive care (BSC);No additional benefit;Pfizer Pharma GmbH;Valid;Valid;First indication;No;Oncology;No additional benefit;;;2019-06-01-D-451;
259;Keytruda;pembrolizumab;Non-small cell lung cancer (NSCLC);Non-small cell lung cancer, after prior chemotherapy;2016-08-15;2017-02-02;2017-02-02;No;No;KEYTRUDA is indicated for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) with PD-L1-expressing tumors in adults who have previously undergone chemotherapy. Patients with EGFR- or ALK-positive tumor mutations should have received an approved therapy for these mutations prior to treatment with KEYTRUDA.;2) Patients for whom treatment with docetaxel, pemetrexed and nivolumab is not indicated;8600.0;13500.0;11050.0;Best supportive care (BSC);No additional benefit;MSD Sharp & Dohme GmbH;Valid;Valid;New application area;No;Oncology;Considerable additional benefit;Overall survival, Progression-free survival, Disease symptomatology, Health-related quality of life, Adverse events;"KEYNOTE 010:
active-controlled, multicenter, open-label, parallel, Phase II/III, RCT (Randomized Controlled Trial)";2016-08-15-D-251;"KEYNOTE 010:  
Docetaxel"
918;Lumykras;sotorasib;Non-small cell lung cancer (NSCLC);Non-small cell lung cancer, KRAS G12C mutation, ≥ 1 previous therapy;2023-02-01;2022-08-04;2023-08-03;No;Yes;Lumykras is used as monotherapy for the treatment of adults with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation in whom progression has been observed after at least one previous systemic therapy.;c1) Adults with advanced non-small cell lung cancer (NSCLC) with KRAS p.G12C mutation after first-line therapy with a PD-1/PD-L1 antibody in combination with platinum-containing chemotherapy or after sequential therapy with a PD-1/PD-L1 antibody and platinum-containing chemotherapy. Adults for whom docetaxel is the appropriate therapy for the individual patient;420.0;910.0;665.0;Patient-specific therapy, taking into account previous therapy and histology, with a choice of afatinib, pemetrexed, erlotinib, docetaxel, docetaxel in combination with ramucirumab, docetaxel in combination with nintedanib and vinorelbine.;Non-quantifiable additional benefit;Amgen Europe B.V.;Valid;Valid;Reassessment: deadline expiration;No;Oncology;Non-quantifiable additional benefit;"Progression-Free Survival, Overall Survival, Objective Response Rate, Symptomatology and Health-Related Quality of Life (EORTC QLQ-C30; EORTC QLQ-LC13; EQ-5D-5L), Duration of Response, Time to Response, Disease Control Rate, Safety and Tolerability, Pharmacokinetics, PFS2, CNS Recurrence, PFS (Investigator-assessed), Biomarker Expression, PRO-CTCAE, FACT-G GP5, PGI-S, PGI-C, BPI-SF";"CodeBreak 200:  
Randomized, open-label, parallel, multicenter, active-controlled Phase III clinical study";2023-02-01-D-913;CodeBreak 200:
1082;Keytruda;pembrolizumab;Non-small cell lung cancer (NSCLC);Non-small cell lung carcinoma, neoadjuvant and adjuvant therapy, monotherapy or combination with platinum-based chemotherapy;2024-05-01;2024-10-17;2024-10-17;No;No;Keytruda is indicated in combination with platinum-based chemotherapy for neoadjuvant treatment and subsequently as monotherapy for adjuvant treatment of resectable non-small cell lung cancer with a high risk of recurrence in adults.;a) Adults with resectable non-small cell lung cancer with tumor cell PD-L1 expression ≥ 1% with high recurrence risk - neoadjuvant and adjuvant therapy;3240.0;3680.0;3460.0;"Neoadjuvant treatment:
Nivolumab in combination with a platinum-based therapy
Followed by adjuvant treatment:
Best supportive care (BSC)";No additional benefit;MSD Sharp & Dohme GmbH;Valid;Valid;New application area;No;Oncology;No additional benefit;Disease-free survival, Overall survival, Adverse events, Disease symptomatology and health status (EORTC QLQ-C30, EORTC QLQ-LC13, and EQ-5D VAS), Health-related quality of life (EORTC QLQ-C30 functional scales);"KEYNOTE 091:  
Randomized, placebo-controlled, Phase III clinical study with parallel groups";2024-05-01-D-1059;"KEYNOTE 091:
Placebo"
1082;Keytruda;pembrolizumab;Non-small cell lung cancer (NSCLC);Non-small cell lung carcinoma, neoadjuvant and adjuvant therapy, monotherapy or combination with platinum-based chemotherapy;2024-05-01;2024-10-17;2024-10-17;No;No;Keytruda is indicated in combination with platinum-based chemotherapy for neoadjuvant treatment and subsequently as monotherapy for adjuvant treatment of resectable non-small cell lung cancer with a high risk of recurrence in adults.;b) Adults with resectable non-small cell lung cancer with tumor cell PD-L1 expression < 1% with high recurrence risk - neoadjuvant and adjuvant therapy;1850.0;2100.0;1975.0;"Patient-specific therapy with selection of
 - preoperative (neoadjuvant) systemic chemotherapy with selection of
 - Cisplatin in combination with a third-generation cytostatic (Vinorelbine or Gemcitabine or Docetaxel or Paclitaxel or Pemetrexed)
  and
 - Carboplatin in combination with a third-generation cytostatic (Vinorelbine or Gemcitabine or Docetaxel or Paclitaxel or Pemetrexed) and
 - simultaneous chemoradiotherapy with platinum-based (Cisplatin or Carboplatin) combination chemotherapy.
 considering the tumor stage, tumor histology, the presence of a Pancoast tumor, and the feasibility of an R0 resection, as well as the prerequisites for the use of Carboplatin.
 Followed by adjuvant treatment:
 Best supportive care (BSC).";No additional benefit;MSD Sharp & Dohme GmbH;Valid;Valid;New application area;No;Oncology;No additional benefit;Disease-free survival, Overall survival, Adverse events, Disease symptomatology and health status (EORTC QLQ-C30, EORTC QLQ-LC13, and EQ-5D VAS), Health-related quality of life (EORTC QLQ-C30 functional scales);"KEYNOTE 091:  
multicenter, Phase III, placebo-controlled, Randomized, triple-blind";2024-05-01-D-1059;"KEYNOTE 091:  
Placebo"
494;Tecentriq;atezolizumab;Non-small cell lung cancer (NSCLC);"NSCLC, non-squamous, first-line, combination with bevacizumab, paclitaxel and carboplatin; maintenance therapy";2019-10-01;2020-04-02;2020-04-02;No;No;Tecentriq is used in combination with bevacizumab, paclitaxel and carboplatin in adult patients for the first-line treatment of metastatic non-small cell lung cancer (NSCLC) with non-squamous histology. In patients with EGFR mutations or ALK-positive NSCLC, Tecentriq in combination with bevacizumab, paclitaxel and carboplatin is only to be used after failure of the corresponding targeted therapies.;"a) Adults with metastatic non-small cell lung cancer with non-squamous histology and a Tumor Proportion Score [TPS] of ≥ 50% (PD-L1 expression) and without EGFR mutations or ALK translocations; first-line therapy";2320.0;2640.0;2480.0;Pembrolizumab as monotherapy;No additional benefit;Roche Pharma AG;Valid;Valid;New application area;No;Oncology;No additional benefit;Overall Survival, Progression-Free Survival (RECIST v1.1), Objective Response Rate (RECIST v1.1), Duration of Response (RECIST v1.1), EORTC Quality of Life Questionnaire-Core 30, EORTC Quality of Life Questionnaire-Lung Cancer Module 13, EQ-5D Visual Analogue Scale, Adverse Events;"IMpower150:
active-controlled, multicenter, open-label, parallel, Phase III, RCT";2019-10-01-D-473;"IMpower150:  
Carboplatin + Paclitaxel + Bevacizumab"
1100;Alecensa;alectinib;Non-small cell lung cancer (NSCLC);Non-small cell lung cancer, ALK+, high risk of recurrence, adjuvant therapy;2024-07-15;2025-01-16;2025-01-16;No;No;Alecensa is used as monotherapy for the adjuvant treatment of adult patients with ALK-positive NSCLC at high risk of recurrence following complete tumor resection.;b) Adults with ALK-positive NSCLC at high risk of recurrence for adjuvant treatment after complete tumor resection following prior adjuvant platinum-based chemotherapy or who are not eligible for such treatment.;230.0;452.0;341.0;Watchful waiting;No additional benefit;Roche Pharma AG;Valid;Valid;New application area;No;Oncology;Major additional benefit;"DFS (investigator-assessed), Overall Survival, DFS rates (after 3, 4, and 5 years), Localization of the first recurrence or a new primary NSCLC, CNS-DFS, PRO: SF-36v2 and EQ5D VAS, Pharmacokinetics, Biomarker, Adverse events; laboratory parameters, vital signs, ECG";"ALINA:  
Phase III; RCT (Randomized Controlled Trial), open, parallel, multicenter";2024-07-15-D-1079;"ALINA:  
Platinum-based chemotherapy"
289;Tafinlar;dabrafenib;Non-small cell lung cancer (NSCLC);Non-small cell lung cancer, BRAF V600 mutation, combination with trametinib;2017-05-01;2017-10-19;2017-10-19;No;No;Dabrafenib (Tafinlar®) in combination with trametinib is indicated for the treatment of adult patients with advanced non-small cell lung cancer with a BRAF V600 mutation.;2b) Patients with previous treatment for whom therapy with docetaxel and pemetrexed is not indicated;80.0;350.0;215.0;Best supportive care (BSC);No additional benefit;Novartis Pharma GmbH;Valid;Valid;New application area;No;Oncology;No additional benefit;FEV1, asthma symptoms, exacerbations, health-related quality of life, adverse events;"Study 1:  
double-blind, parallel, Randomized Controlled Trial (RCT)";2017-05-01-D-285;"Study 1:
Placebo"
170;Giotrif;afatinib;Non-small cell lung cancer (NSCLC);Non-small cell lung cancer, EGFR mutation, EGFR-TKI-naïve patients;2015-05-15;2014-05-08;2015-11-05;No;Yes;GIOTRIF as monotherapy is used to treat EGFR-TKI-naïve adult patients with locally advanced and/or metastatic non-small cell lung cancer (NSCLC) with activating EGFR mutations.;1a) Non-pretreated patients with ECOG performance status 0 or 1. Patient group with EGFR mutation Del19;1530.0;3590.0;2560.0;"- Gefitinib or erlotinib or
- cisplatin in combination with a third-generation cytostatic (vinorelbine or gemcitabine or docetaxel or paclitaxel or pemetrexed), taking into account the approval status, or
- carboplatin in combination with a third-generation cytostatic (only for patients with an increased risk of cisplatin-induced side effects in the context of combination therapy";Major additional benefit;Boehringer Ingelheim Pharma GmbH & Co. KG;Valid;Valid;Reassessment: deadline expiration;No;Oncology;Major additional benefit;progression‑free survival, overall survival, objective response rate, symptomatology (EORTC QLQ‑C30, EORTC QLQ‑LC13), health‑related quality of life (EORTC QLQ‑C30, EQ‑5D), adverse events;"LUX-Lung 3 (NCT00949650):  
Randomized controlled trial (RCT), open, parallel, active controlled, Phase III study, multicentric (multinational).  

LUX-Lung 6 (NCT01121393):  
RCT, open, parallel, active controlled, Phase III study, multicentric (oligonational).";2015-05-15-D-163;"LUX-Lung 3 (NCT00949650):  
Cisplatin + Pemetrexed  

LUX-Lung 6 (NCT01121393):  
Cisplatin + Gemcitabine"
1134;Braftovi;encorafenib;Non-small cell lung cancer (NSCLC);Non-small cell lung cancer, advanced, BRAF V600E mutation, combination with binimetinib;2024-10-01;2025-03-20;2025-03-20;No;No;Encorafenib in combination with Binimetinib is used in adult patients with advanced non-small cell lung cancer (NSCLC) with a BRAF V600E mutation.;"a) Adults with advanced non-small cell lung cancer (NSCLC) with PD-L1 expression ≥ 50% and a BRAF V600E mutation; first-line therapy";31.0;102.0;67.0;"− Dabrafenib in combination with trametinib, or
− pembrolizumab as monotherapy, or
− atezolizumab as monotherapy, or
− cemiplimab as monotherapy, or
− nivolumab in combination with ipilimumab and 2 cycles of platinum-based chemotherapy (only for patients with ECOG PS 0–1), or
− pembrolizumab in combination with pemetrexed and platinum-based chemotherapy (only for patients with ECOG PS 0–1), or
− atezolizumab in combination with bevacizumab, paclitaxel, and carboplatin (only for patients with ECOG PS 0–1), or
− atezolizumab in combination with nab-paclitaxel and carboplatin (only for patients with ECOG PS 0–1), or
− cemiplimab in combination with platinum-based chemotherapy (only for patients with ECOG PS 0–1), or
− durvalumab in combination with tremelimumab and platinum-based chemotherapy (only for patients with ECOG PS 0–1).";No additional benefit;Pierre Fabre Pharma GmbH;Valid;Valid;New application area;No;Oncology;No additional benefit;;;2024-10-01-D-1114;
1165;Tagrisso;osimertinib;Non-small cell lung cancer (NSCLC);Non-small cell lung cancer, EGFR mutations, after platinum-based radiochemotherapy;2025-01-15;2025-07-01;2025-07-01;No;No;;;;;;;;AstraZeneca GmbH;In progress;In progress;New application area;No;Oncology;;;;;
952;Libtayo;cemiplimab;Non-small cell lung cancer (NSCLC);Non-small cell lung cancer, first-line, PD-L1 expression ≥ 1%, combination with platinum-based chemotherapy;2023-05-01;2023-10-19;2023-10-19;No;No;"Libtayo is indicated in combination with platinum-based chemotherapy for the first-line treatment of adult patients with NSCLC that expresses PD-L1 (in ≥ 1% of tumor cells) and has no EGFR, ALK or ROS1 aberrations. The treatment is intended for:
- Patients with locally advanced NSCLC who are not candidates for definitive radiochemotherapy, or
- Patients with metastatic NSCLC";"a) Adults with locally advanced or metastatic NSCLC with PD-L1 expression ≥ 50% without EGFR, ALK or ROS1 aberrations; first-line therapy";4860.0;6680.0;5770.0;"- Pembrolizumab as monotherapy or
- atezolizumab as monotherapy or
- cemiplimab as monotherapy or
- nivolumab in combination with ipilimumab and 2 cycles of platinum-based chemotherapy (only for patients with ECOG PS 0-1) or
- pembrolizumab in combination with carboplatin and either paclitaxel or nab-paclitaxel (only for patients with ECOG PS 0-1 and squamous NSCLC) or
- pembrolizumab in combination with pemetrexed and platinum-containing chemotherapy (only for patients with ECOG PS 0-1 and non-squamous NSCLC) or
- atezolizumab in combination with bevacizumab, paclitaxel and carboplatin (only for patients with ECOG PS 0-1 and non-squamous NSCLC) or
- atezolizumab in combination with nab-paclitaxel and carboplatin (only for patients with ECOG PS 0-1 and non-squamous NSCLC)";No additional benefit;Sanofi-Aventis Deutschland GmbH;Valid;Valid;New application area;No;Oncology;No additional benefit;Overall Survival, Progression-Free Survival, Objective Response Rate, Duration of Response, Patient-reported HRQoL using EORTC QLQ-C30 and EORTC QLQ-LC13, Adverse Events;"R2810-ONC-16113, Part 2:  
active-controlled, double-blind, multicenter, parallel, Phase III, Randomized";2023-05-01-D-935;"R2810-ONC-16113, Part 2:  
Placebo/CTx (Platinum-based chemotherapy)"
770;Gavreto;pralsetinib;Non-small cell lung cancer (NSCLC);Non-small cell lung cancer, non-small cell, RET-fusion+;2021-12-15;2022-06-16;2022-06-16;No;No;Gavreto is used as monotherapy for the treatment of adult patients with rearranged-during-transfection (RET) fusion-positive advanced non-small cell lung cancer (NSCLC) who have not previously been treated with a RET inhibitor.;"a) Adults with RET fusion-positive, advanced non-small cell lung cancer (NSCLC) with PD-L1 expression ≥ 50% of tumor cells; first-line therapy";30.0;90.0;60.0;Pembrolizumab as monotherapy;No additional benefit;Roche Pharma AG;Valid;Valid;First indication;No;Oncology;No additional benefit;Determination of the MTD, Determination of the RP2D, Evaluation of safety and tolerability, Determination of the ORR, Pharmacokinetics, Pharmacodynamics, Antineoplastic activity, DOR, CBR, DCR, PFS, OS, Changes in patient-reported outcomes;"ARROW:  
Multicenter, international, single-arm, open-label Phase I/II study

";2021-12-15-D-757;ARROW: Since this is a single-arm study, there is no direct comparator arm or study comparator.
262;Xalkori;crizotinib;Non-small cell lung cancer (NSCLC);Non-small cell lung cancer, ROS1+;2016-10-01;2017-03-16;2017-03-16;No;No;XALKORI is used in adults for the treatment of ROS1-positive, advanced non-small cell lung cancer (NSCLC);2a) Previously treated patients with ROS1-positive, advanced non-small cell lung cancer (NSCLC). Patients who are eligible for treatment with docetaxel or pemetrexed;90.0;190.0;140.0;Docetaxel or pemetrexed;No additional benefit;Pfizer Pharma GmbH;Valid;Valid;New application area;No;Oncology;No additional benefit;Objective Response Rate (ORR), Disease Control Rate (DCR), Duration of Response (DR), Time to Tumor Response (TTR), Progression-Free Survival (PFS), Time to Tumor Progression (TTP), Overall Survival (OS), Pharmacokinetics, Adverse Events, Health-Related Quality of Life (EORTC QLQ-C30 and EORTC QLQ-LC13), Changes in Laboratory Parameters, Adverse Events (Grade 3, 4 or 5), Survival Status (deceased/alive);Both Indication A and Indication B studies included in the dossier show heterogeneous designs. For Indication A, the designs comprise single-arm open studies and randomized controlled studies, while for Indication B, retrospective cohort studies were conducted. These details are documented in the corresponding tables and text sections (e.g., Table 4-36, 4-37).;2016-10-01-D-261;"Indication A:  
Carboplatin + Pemetrexed  
Cisplatin + Pemetrexed  

Indication B:  
Docetaxel  
Pemetrexed"
806;Lorviqua;lorlatinib;Non-small cell lung cancer (NSCLC);Non-small cell lung cancer, ALK+, first-line;2022-03-01;2022-09-01;2022-09-01;No;No;Lorviqua as monotherapy is used to treat adult patients with anaplastic lymphoma kinase (ALK)-positive, advanced non-small cell lung cancer (NSCLC) who have not previously been treated with an ALK inhibitor.;As area of application according to approval;390.0;1310.0;850.0;"- Alectinib or
- brigatinib";No additional benefit;Pfizer Pharma GmbH;Valid;Valid;New application area;No;Oncology;No additional benefit;;;2022-03-01-D-792;
547;Alunbrig;brigatinib;Non-small cell lung cancer (NSCLC);NSCLC, ALK+, ALK-inhibitor-naive patients;2020-05-01;2020-10-15;2020-10-15;No;No;Alunbrig is indicated as monotherapy in adult patients with anaplastic lymphoma kinase (ALK)-positive, advanced non-small cell lung cancer (NSCLC) who have not previously been treated with an ALK inhibitor.;a) Adult patients with anaplastic lymphoma kinase (ALK)-positive, advanced, non-small cell lung cancer with brain metastases who have not previously been treated with an ALK inhibitor;420.0;910.0;665.0;"- Crizotinib or
- alectinib";Considerable additional benefit;Takeda GmbH;Valid;Valid;New application area;No;Oncology;Considerable additional benefit;Progression‐free survival assessed by BIRC, Tumor response assessed by BIRC (ORR, duration of response, time to response, disease control rate), Intracranial tumor response assessed by BIRC, Intracranial progression‐free survival assessed by BIRC, Overall survival, Safety and tolerability;"ALTA-1L:  
controlled, open-label, parallel, multicenter, phase III study";2020-05-01-D-542;"ALTA-1L:  
Crizotinib"
405;Imfinzi;durvalumab;Non-small cell lung cancer (NSCLC);Non-small cell lung cancer, maintenance therapy;2018-10-15;2019-04-04;2019-04-04;No;No;"IMFINZI is indicated as monotherapy for the treatment of locally advanced,
unresectable non-small cell lung cancer (NSCLC) in adults whose tumors express
tumors express PD-L1 in ≥ 1% of tumor cells and whose disease has not progressed after platinum-based
disease has not progressed after platinum-based radiochemotherapy.";As area of application according to approval;1600.0;1800.0;1700.0;Best supportive care (BSC);Considerable additional benefit;AstraZeneca GmbH;Valid;Valid;First indication;No;Oncology;Considerable additional benefit;Overall Survival, Progression-Free Survival (according to BICR assessment per RECIST 1.1), Proportion of patients alive at 24 months after randomization, Proportion of patients alive at 12 months after randomization, Objective Response Rate, Proportion of patients alive without progression at 12 and 18 months after randomization, Distant metastases (time to death or time to occurrence of distant metastases), Time to subsequent therapy;"PACIFIC:  
Randomized, double-blind, multicenter, placebo-controlled Phase III study with a randomization ratio of 2:1";2018-10-15-D-402;"PACIFIC:  
Placebo"
87;Giotrif;afatinib;Non-small cell lung cancer (NSCLC);Non-small cell lung cancer, EGFR mutation, EGFR-TKI-naïve patients;2013-11-15;2014-05-08;2014-05-08;No;No;Giotrif® as monotherapy is used for the treatment of EGFR-TKI-naive adult patients with locally advanced and/or metastatic non-small cell lung cancer (NSCLC) with activating EGFR mutations.;1b) Previously untreated patients with ECOG performance status 0 or 1, patient group with EGFR mutation L858R;120.0;830.0;475.0;"- Gefitinib or erlotinib or
- cisplatin in combination with a third-generation cytostatic (Vinorelbine, Gemcitabine, Docetaxel, Paclitaxel, Pemetrexed) considering the respective approved indication";Minor additional benefit;Boehringer Ingelheim Pharma GmbH & Co. KG;Repealed;Repealed;First indication;No;Oncology;Considerable additional benefit;Progression-free survival, Overall Survival, Objective Response Rate, Symptomatology (EORTC QLQ-C30, EORTC QLQ-LC13), Health-related quality of life (EORTC QLQ-C30, EQ-5D), Adverse events;"LUX-Lung 3 (NCT00949650):
Randomized Controlled Trial (RCT), open-label, parallel, active-controlled, Phase III study, multicenter, multinational

LUX-Lung 6 (NCT01121393):
Randomized Controlled Trial (RCT), open-label, parallel, active-controlled, Phase III study, multicenter, oligo-national";2013-11-15-D-082;"NCT00949650:  
Cisplatin + Pemetrexed  

NCT01121393:  
Cisplatin + Gemcitabine"
1107;Tagrisso;osimertinib;Non-small cell lung cancer (NSCLC);Non-small cell lung cancer, first-line, combination with pemetrexed and platinum-based chemotherapy;2024-08-01;2025-02-06;2025-02-06;No;No;Tagrisso is indicated in combination with pemetrexed and platinum-based chemotherapy for the first-line treatment of adult patients with advanced NSCLC whose tumors have EGFR mutations, either a deletion in exon 19 or a substitution mutation in exon 21 (L858R).;As area of application according to approval;840.0;2720.0;1780.0;"Afatinib (only for patients with the activating EGFR mutation deletion in exon 19) or 
osimertinib";No additional benefit;AstraZeneca GmbH;Valid;Valid;New application area;No;Oncology;No additional benefit;Progression-free survival, Overall survival, EORTC Quality of Life Questionnaire C30, EORTC Quality of Life Questionnaire Lung Cancer 13, EQ-5D Visual Analog Scale, Patient Global Impression of Severity, Adverse Events, Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events;"FLAURA-2:  
Randomized, open-label, sponsor-blinded, controlled Phase III study";2024-08-01-D-1082;"FLAURA-2:  
Chemo"
434;Alunbrig;brigatinib;Non-small cell lung cancer (NSCLC);Non-small cell lung cancer, ALK+, after crizotinib pre-therapy;2019-01-15;2019-07-04;2019-07-04;No;No;Alunbrig is indicated as monotherapy in adult patients with anaplastic lymphoma kinase (ALK)-positive, advanced non-small cell lung cancer (NSCLC) who have previously been treated with crizotinib.;As area of application according to approval;160.0;1060.0;610.0;Ceritinib or alectinib;No additional benefit;Takeda GmbH;Valid;Valid;First indication;No;Oncology;No additional benefit;Objective Response Rate (ORR), assessed by the investigator, assessed by BIRC, Intracranial response, assessed by BIRC (ORR and PFS), Time to response, Duration of response, Disease control rate, Progression-free survival, Overall survival, assessed by BIRC and the investigator, Safety, Health-related quality of life according to EORTC QLQ-C30 (Version 3.0), Determination of the recommended Phase II dose of Brigatinib, Determination of the maximum tolerated dose of Brigatinib, Safety profile, Tolerability of Brigatinib, Dose-limiting toxicity of Brigatinib;"ALTA:  
Randomized, open-label Phase II study with parallel groups (1:1)

AP26113-11-101:  
Multicenter, open-label, non-randomized Phase I/II dose-finding study";2019-01-15-D-434;"ALTA: No external comparator arm; the study internally compares two dosing regimens (90 mg vs. 180 mg after a 7-day lead-in period).

AP26113-11-101: Single-arm, dose-finding study without a separate comparator group."
1135;Mektovi;binimetinib;Non-small cell lung cancer (NSCLC);Non-small cell lung cancer, advanced, BRAF V600E mutation, combination with encorafenib;2024-10-01;2025-03-20;2025-03-20;No;No;Binimetinib in combination with Encorafenib is used in adult patients with advanced non-small cell lung cancer (NSCLC) with a BRAF V600E mutation.;"b) Adults with advanced non-small cell lung cancer (NSCLC) with PD-L1 expression < 50% and a BRAF V600E mutation; first-line therapy";90.0;251.0;171.0;"− Dabrafenib in combination with trametinib, or
− pembrolizumab in combination with pemetrexed and platinum-based chemotherapy (only for patients with ECOG PS 0–1), or
− atezolizumab as monotherapy (only for patients with PD-L1 expression ≥ 10% in tumor-infiltrating immune cells), or
− atezolizumab in combination with bevacizumab, paclitaxel, and carboplatin (only for patients with ECOG PS 0–1), or
− atezolizumab in combination with nab-paclitaxel and carboplatin (only for patients with ECOG PS 0–1), or
− nivolumab in combination with ipilimumab and 2 cycles of platinum-based chemotherapy (only for patients with ECOG PS 0–1),
− cemiplimab in combination with platinum-based chemotherapy (only for patients with ECOG PS 0–1),
− durvalumab in combination with tremelimumab and platinum-based chemotherapy (only for patients with ECOG PS 0–1)";No additional benefit;Pierre Fabre Pharma GmbH;Valid;Valid;New application area;No;Oncology;No additional benefit;;;2024-10-01-D-1113;
230;Giotrif;afatinib;Non-small cell lung cancer (NSCLC);Non-small cell lung carcinoma, squamous cell histology;2016-05-01;2016-10-20;2016-10-20;No;No;Giotrif® as monotherapy is used for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) with squamous histology that progresses during or after platinum-based chemotherapy.;a) Patients with locally advanced and/or metastatic NSCLC with squamous cell histology with progression during or after platinum-based chemotherapy for whom docetaxel therapy is indicated;2100.0;5520.0;3810.0;Docetaxel;No additional benefit;Boehringer Ingelheim Pharma GmbH & Co. KG;Valid;Valid;New application area;No;Oncology;No additional benefit;Progression-free survival, Overall Survival, Objective Response Rate, Disease Control Rate, Symptomatology (EORTC QLQ-C30, EORTC QLQ-LC13), Health-Related Quality of Life (EORTC QLQ-C30, EQ-5D), Adverse Events;"LUX-Lung 8 (NCT01523587):  
active-controlled, multicenter multinational, open-label, parallel, Phase III study, RCT (Randomized Controlled Trial)";2016-05-01-D-226;"LUX-Lung 8 (NCT01523587):  
Erlotinib"
1135;Mektovi;binimetinib;Non-small cell lung cancer (NSCLC);Non-small cell lung cancer, advanced, BRAF V600E mutation, combination with encorafenib;2024-10-01;2025-03-20;2025-03-20;No;No;Binimetinib in combination with Encorafenib is used in adult patients with advanced non-small cell lung cancer (NSCLC) with a BRAF V600E mutation.;"c) Adults with advanced non-small cell lung cancer (NSCLC) with a BRAF V600E mutation; after first-line therapy";1.0;123.0;62.0;− Dabrafenib in combination with trametinib;No additional benefit;Pierre Fabre Pharma GmbH;Valid;Valid;New application area;No;Oncology;No additional benefit;;;2024-10-01-D-1113;
232;Opdivo;nivolumab;Non-small cell lung cancer (NSCLC);Non-small cell lung carcinoma, non-squamous cell histology, after prior chemotherapy;2016-05-01;2016-10-20;2016-10-20;No;No;OPDIVO is indicated for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) after prior chemotherapy in adults.;2) Patients for whom treatment with docetaxel, pemetrexed, gefitinib, erlotinib and crizotinib is not indicated;8130.0;12130.0;10130.0;Best supportive care (BSC);No additional benefit;Bristol-Myers Squibb GmbH & Co. KGaA;Valid;Valid;New application area;No;Oncology;Considerable additional benefit;Overall Survival (OS), Index value of disease-related symptoms according to LCSS, Health-related quality of life according to LCSS, Generic quality of life according to EQ-5D, Safety and tolerability (adverse events);"CA209-057:  
open, parallel, Randomized controlled trial";2016-05-01-D-231;"CA209-057:  
Docetaxel"
937;Imfinzi;durvalumab;Non-small cell lung cancer (NSCLC);Non-small cell lung cancer, EGFR/ALK-negative, first-line, combination with tremelimumab and platinum-based chemotherapy;2023-04-01;2023-10-05;2023-10-05;No;No;IMFINZI in combination with tremelimumab and platinum-based chemotherapy is indicated in adults for the first-line treatment of metastatic NSCLC without sensitizing EGFR mutations or ALK-positive mutations.;"a) Adults with metastatic NSCLC with PD-L1 expression ≥ 50% without genomic EGFR or ALK tumor mutations; first-line therapy";3860.0;6850.0;5355.0;"- Pembrolizumab as monotherapy or
- atezolizumab as monotherapy or
- cemiplimab as monotherapy or
- nivolumab in combination with ipilimumab and 2 cycles of platinum-based chemotherapy (only for patients with ECOG PS 0-1) or
- pembrolizumab in combination with carboplatin and either paclitaxel or nab-paclitaxel (only for patients with ECOG PS 0-1 and squamous NSCLC) or
- pembrolizumab in combination with pemetrexed and platinum-containing chemotherapy (only for patients with ECOG PS 0-1 and non-squamous NSCLC) or
- atezolizumab in combination with bevacizumab, paclitaxel and carboplatin (only for patients with ECOG PS 0-1 and non-squamous NSCLC) or
- atezolizumab in combination with nab-paclitaxel and carboplatin (only for patients with ECOG PS 0-1 and non-squamous NSCLC)";No additional benefit;AstraZeneca GmbH;Valid;Valid;New application area;No;Oncology;No additional benefit;Overall Survival, Progression-free Survival, Objective Response Rate, Progression-free Survival 2, EORTC QLQ-C30, EORTC QLQ-LC13, EQ-5D Visual Analog Scale, Patient Global Impression of Change, Adverse Events;"POSEIDON:  
Randomized, controlled, open-label, multicenter, global Phase III study with allocation ratio of 1:1:1";2023-04-01-D-921;"POSEIDON:  
CTx (Platinum-based chemotherapy)"
631;Opdivo;nivolumab;Non-small cell lung cancer (NSCLC);Non-small cell lung cancer, combination with ipilimumab and platinum-based chemotherapy, first-line;2020-12-15;2021-06-03;2021-06-03;No;No;Opdivo is indicated in combination with ipilimumab and 2 cycles of platinum-based chemotherapy for the first-line treatment of metastatic non-small cell lung cancer (NSCLC) in adults whose tumors do not have a sensitizing EGFR mutation or ALK translocation.;"a) Adult patients with metastatic non-small cell lung cancer (NSCLC) with a Tumor Proportion Score [TPS] of ≥ 50% (PD-L1 expression) and without EGFR mutations or ALK translocations; first-line treatment";3710.0;4680.0;4195.0;Pembrolizumab as monotherapy;No additional benefit;Bristol-Myers Squibb Pharma EEIG;Valid;Valid;New application area;No;Oncology;Minor additional benefit;Overall Survival, Disease-related symptoms according to LCSS, Health-related quality of life according to LCSS, Health status according to EQ-5D-VAS, Adverse events;"CA209-9LA:  
open, parallel, Randomized controlled study";2020-12-15-D-628;"CA209-9LA:  
Platinum-based chemotherapy"
770;Gavreto;pralsetinib;Non-small cell lung cancer (NSCLC);Non-small cell lung cancer, non-small cell, RET-fusion+;2021-12-15;2022-06-16;2022-06-16;No;No;Gavreto is used as monotherapy for the treatment of adult patients with rearranged-during-transfection (RET) fusion-positive advanced non-small cell lung cancer (NSCLC) who have not previously been treated with a RET inhibitor.;c) Adults with RET fusion-positive, advanced non-small cell lung cancer (NSCLC) after first-line therapy with a PD-1/PD-L1 antibody as monotherapy;5.0;20.0;12.5;"- Cisplatin in combination with a third-generation cytostatic (vinorelbine or gemcitabine or docetaxel or paclitaxel or pemetrexed (except in the case of predominantly squamous histology)) or
- carboplatin in combination with a third-generation cytostatic agent (vinorelbine or gemcitabine or docetaxel or paclitaxel or pemetrexed (except in the case of predominantly squamous histology)) or
- carboplatin in combination with nab-paclitaxel or
- monotherapy with gemcitabine or vinorelbine (only for patients with ECOG performance status 2 as an alternative to platinum-based combination treatment)";No additional benefit;Roche Pharma AG;Valid;Valid;First indication;No;Oncology;No additional benefit;Determination of the MTD, Determination of the RP2D, Evaluation of safety and tolerability, Determination of the ORR, Pharmacokinetics, Pharmacodynamics, Antineoplastic activity, DOR, CBR, DCR, PFS, OS, Changes in patient-reported outcomes;"ARROW:  
Multicenter, international, single-arm, open Phase I/II study";2021-12-15-D-757;ARROW: As it is a single-arm study, there is no direct comparator arm or study comparator.
867;Tabrecta;capmatinib;Non-small cell lung cancer (NSCLC);Non-small cell lung cancer, METex14 skipping mutation, pre-treated patients;2022-08-15;2023-02-02;2023-02-02;No;No;Tabrecta as monotherapy is used to treat adult patients with advanced non-small cell lung cancer (NSCLC) with alterations leading to METex14 skipping (exon 14 skipping in the mesenchymal-epithelial transition factor gene) who require systemic therapy following treatment with immunotherapy and/or platinum-based chemotherapy.;c) Adults with advanced non-small cell lung cancer (NSCLC) with METex14 skipping (exon 14 skipping in the mesenchymal-epithelial transition factor gene) mutation after first-line therapy with a PD-1/PD-L1 antibody in combination with platinum-containing chemotherapy or after sequential therapy with a PD-1/PD-L1 antibody and platinum-containing chemotherapy;400.0;670.0;535.0;"Patient-specific therapy taking into account previous therapy and histology with selection of
- afatinib,
- pemetrexed,
- erlotinib,
- docetaxel,
- docetaxel in combination with ramucirumab,
- docetaxel in combination with nintedanib and
- vinorelbine";No additional benefit;Novartis Pharma GmbH;Valid;Valid;First indication;No;Oncology;No additional benefit;Overall survival (OS), Progression-free survival (PFS), Overall response rate (ORR), Time to CNS progression (CNSprog), Time to treatment discontinuation due to adverse events (TDAE), Unplanned or prolonged hospitalization (upHOSP), Unplanned or prolonged hospitalization or death (upHOSP + D);Non-randomized, comparative study examining efficacy and safety of Capmatinib in patients with locally advanced or metastatic non-small cell lung carcinoma (NSCLC) with METex14-skipping mutation. International data from GEOMETRY mono-1 study (Capmatinib) compared to retrospectively collected patient data from nNGM cohort (German standard of care or suitable comparator therapy). Study design includes prospectively collected data in the Capmatinib group and retrospective data from clinical practice according to G-BA guidelines.;2022-08-15-D-855;The comparison arm is based on patient data from GEOMETRY mono-1 study and nNGM cohort, which represent the German standard of care (SoC) and the defined appropriate comparative therapy (zVT). The patients were selected according to strict, G-BA-compliant inclusion and exclusion criteria and serve as an external control arm in comparison to the Capmatinib group.
232;Opdivo;nivolumab;Non-small cell lung cancer (NSCLC);Non-small cell lung carcinoma, non-squamous cell histology, after prior chemotherapy;2016-05-01;2016-10-20;2016-10-20;No;No;OPDIVO is indicated for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) after prior chemotherapy in adults.;1) Patients for whom therapy with docetaxel, pemetrexed, gefitinib, erlotinib or crizotinib is indicated;3700.0;9700.0;6700.0;"- Docetaxel or
- pemetrexed or
- gefitinib or erlotinib (only for patients with activating EGFR mutations who have not yet been pretreated with afatinib, gefitinib or erlotinib) or
- crizotinib (only for patients with activating ALK mutations who have not yet been pretreated with crizotinib)";Considerable additional benefit;Bristol-Myers Squibb GmbH & Co. KGaA;Valid;Valid;New application area;No;Oncology;Considerable additional benefit;Overall Survival (OS), Index value of disease-related symptoms according to LCSS, Health-related quality of life according to LCSS, Generic quality of life according to EQ-5D, Safety and tolerability (adverse events);"CA209-057:  
open, parallel, Randomized controlled trial";2016-05-01-D-231;"CA209-057:  
Docetaxel"
799;Lumykras;sotorasib;Non-small cell lung cancer (NSCLC);Non-small cell lung cancer, KRAS G12C mutation, ≥ 1 previous therapy;2022-02-15;2022-08-04;2022-08-04;No;No;Lumykras is used as monotherapy for the treatment of adults with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation in whom progression has been observed after at least one previous systemic therapy.;c) Adults with advanced non-small cell lung cancer (NSCLC) with KRAS p.G12C mutation after first-line therapy with a PD-1/PD-L1 antibody in combination with platinum-containing chemotherapy or after sequential therapy with a PD-1/PD-L1 antibody L1 antibodies and platinum-containing chemotherapy;420.0;910.0;665.0;Patient-specific therapy taking into account previous therapy and histology, selecting afatinib, pemetrexed, erlotinib, docetaxel, docetaxel in combination with ramucirumab, docetaxel in combination with nintedanib and vinorelbine;No additional benefit;Amgen Europe B.V.;Changed;Changed;First indication;No;Oncology;No additional benefit;;;2022-02-15-D-787;
1134;Braftovi;encorafenib;Non-small cell lung cancer (NSCLC);Non-small cell lung cancer, advanced, BRAF V600E mutation, combination with binimetinib;2024-10-01;2025-03-20;2025-03-20;No;No;Encorafenib in combination with Binimetinib is used in adult patients with advanced non-small cell lung cancer (NSCLC) with a BRAF V600E mutation.;"b) Adults with advanced non-small cell lung cancer (NSCLC) with PD-L1 expression < 50% and a BRAF V600E mutation; first-line therapy";90.0;251.0;171.0;"− Dabrafenib in combination with trametinib, or
− pembrolizumab in combination with pemetrexed and platinum-based chemotherapy (only for patients with ECOG PS 0–1), or
− atezolizumab as monotherapy (only for patients with PD-L1 expression ≥ 10% in tumor-infiltrating immune cells), or
− atezolizumab in combination with bevacizumab, paclitaxel, and carboplatin (only for patients with ECOG PS 0–1), or
− atezolizumab in combination with nab-paclitaxel and carboplatin (only for patients with ECOG PS 0–1), or
− nivolumab in combination with ipilimumab and 2 cycles of platinum-based chemotherapy (only for patients with ECOG PS 0–1),
− cemiplimab in combination with platinum-based chemotherapy (only for patients with ECOG PS 0–1),
− durvalumab in combination with tremelimumab and platinum-based chemotherapy (only for patients with ECOG PS 0–1)";No additional benefit;Pierre Fabre Pharma GmbH;Valid;Valid;New application area;No;Oncology;No additional benefit;;;2024-10-01-D-1114;
1116;Tevimbra;tislelizumab;Non-small cell lung cancer (NSCLC);Non-small cell lung cancer (NSCLC), first-line, squamous, combination with carboplatin and paclitaxel or nab-paclitaxel;2025-01-01;2025-06-15;2025-06-15;No;No;Not specified (assessment in progress);;;;;;;BeiGene Germany GmbH;In progress;In progress;New application area;No;Oncology;;;;;
224;Tagrisso;osimertinib;Non-small cell lung cancer (NSCLC);Non-small cell lung cancer, T790M-EGFR mutation;2016-03-15;2016-09-15;2016-09-15;No;No;TAGRISSO is indicated for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) and a positive epidermal growth factor receptor (EGFR) T790M mutation.;1a) Patients after pretreatment with an EGFR tyrosine kinase inhibitor - cytotoxic chemotherapy as directed by the doctor;560.0;2730.0;1645.0;"- Cytotoxic chemotherapy according to the doctor’s instructions (taking into account the approval status in conjunction with the prescribability of drugs in off-label indications in accordance with Annex VI of the Drug Guideline) or, if applicable
- Best supportive care (BSC) for patients who have already received cytotoxic chemotherapy as an alternative to further cytotoxic chemotherapy.";No additional benefit;AstraZeneca GmbH;Changed;Changed;First indication;No;Oncology;No additional benefit;FEV1, asthma symptoms, exacerbations, health-related quality of life, adverse events, morbidity, objective response rate (ORR), best overall response (BOR), progression-free survival (PFS), safety, AEs, SAEs, treatment discontinuations due to AEs, AEs with CTCAE grade ≥3, AEs with a frequency of ≥10%, exploratory endpoints, health-related quality of life and patient-reported symptoms, safety/tolerability, ORR, overall survival, progression-free survival, disease control rate, quality of life, symptomatology;"Study 1:  
Randomized Controlled Trial (RCT), double-blind, parallel";2016-03-15-D-219;"Study 1:  
Placebo"
285;Alecensa;alectinib;Non-small cell lung cancer (NSCLC);Non-small cell lung cancer, ALK+, after crizotinib pre-therapy;2017-05-01;2017-10-19;2017-10-19;No;No;Alecensa is used as monotherapy for the treatment of anaplastic lymphoma kinase (ALK)-positive, advanced non-small cell lung cancer (NSCLC) in adult patients who have previously been treated with crizotinib.;a) Patients who are eligible for treatment with docetaxel or pemetrexed or ceritinib;160.0;1060.0;610.0;"- Docetaxel or
- pemetrexed or
- ceritinib";Minor additional benefit;Roche Pharma AG;Valid;Valid;First indication;No;Oncology;Minor additional benefit;Overall Response Rate (assessed by IRC), Overall Response Rate (assessed by Investigator), Disease Control Rate (DCR), Duration of Response (DOR), Progression-Free Survival (PFS), Overall Survival (OS), Tolerability (AEs, SAEs, AEs leading to study discontinuation, AESI), Health-Related Quality of Life assessed by EORTC QLQ-C30/LC13, CNS Response (CORR, CDOR, CPR), Overall Response Rate (assessed by IRC) in patients pretreated with chemotherapy, Overall Response Rate (assessed by IRC) in treatment‐naïve patients, Progression-Free Survival (assessed by IRC and investigator), Progression-Free Survival, Objective Response Rate (ORR), Duration of Response (DR), Time to Response (TTR), 6-Month and 1-Year Survival Probability, Adverse Events, Patient Reported Outcomes (PRO) (Quality of Life, Lung Cancer-Specific Symptoms, Health Status), Safety/Tolerability;"NP28673:
Open-label, single-arm Phase I/II study in adult patients with ALK-positive NSCLC who have progressed on Crizotinib

NP28761:
Open-label, single-arm Phase I/II study in adult patients with locally advanced (AJCC stage IIIB) or metastatic (AJCC stage IV) ALK-positive NSCLC who were treated after progression on Crizotinib";2017-05-01-D-281;"NP28673:  
Pemetrexed + Cisplatin  
Pemetrexed + Carboplatin  

NP28761:  
Crizotinib"
807;Tepmetko;tepotinib;Non-small cell lung cancer (NSCLC);Non-small cell lung cancer, METex14 skipping, pre-treated patients;2022-03-01;2022-09-01;2022-09-01;No;No;Tepmetko is used in adult patients with advanced non-small cell lung cancer (NSCLC) with alterations leading to METex14 skipping (exon 14 skipping in the mesenchymal-epithelial transition factor gene) who require systemic therapy following platinum-based chemotherapy and/or immunotherapy.;a) Adults with advanced non-small cell lung cancer (NSCLC) with MET tyrosine kinase receptor exon 14 (METex14) skipping changes after first-line therapy with a PD-1/PD-L1 antibody as monotherapy;80.0;130.0;105.0;"- Cisplatin in combination with a third-generation cytostatic (vinorelbine or gemcitabine or docetaxel or paclitaxel or pemetrexed (except in the case of predominantly squamous histology)) or
- carboplatin in combination with a third-generation cytostatic agent (vinorelbine or gemcitabine or docetaxel or paclitaxel or pemetrexed (except for predominantly squamous histology)) or
- carboplatin in combination with nab-paclitaxel or
- monotherapy with gemcitabine or vinorelbine (only for patients with ECOG performance status 2 as an alternative to platinum-based combination treatment)";No additional benefit;Merck Europe B.V.;Valid;Valid;First indication;No;Oncology;No additional benefit;Objective Response (IRC), Objective Response (Investigator), Duration of Response (IRC, Investigator), Objective Disease Control (IRC, Investigator), Progression-Free Survival (IRC, Investigator), Overall Survival, Patient-Reported Outcome: EQ-5D, EORTC QLQ-C30, EORTC QLQ-LC13, Safety and Tolerability: Adverse Events;"VISION:  
Single-arm, open-label, multicenter Phase II study";2022-03-01-D-781;"VISION:
Since this is a single-arm study, no direct comparator is planned. The benefit assessment is therefore based on internal and historical comparative data."
339;Alecensa;alectinib;Non-small cell lung cancer (NSCLC);Non-small cell lung cancer, ALK+, first-line;2018-01-01;2018-06-21;2018-06-21;No;No;Alecensa is used as monotherapy for the first-line treatment of anaplastic lymphoma kinase (ALK)-positive, advanced non-small cell lung cancer (NSCLC) in adult patients.;As area of application according to approval;350.0;850.0;600.0;Crizotinib;Non-quantifiable additional benefit;Roche Pharma AG;Valid;Valid;New application area;No;Oncology;Non-quantifiable additional benefit;"Progression-Free Survival (PFS; Investigator-assessed), Progression-Free Survival, IRC-assessed, Time to CNS Progression (IRC-assessed), Objective Response Rate (ORR, Investigator-assessed), Duration of Response (DOR), Overall Survival (OS), CNS Response (CORR, IRC-assessed), Duration of CNS Response (CDOR, IRC-assessed), Symptoms assessed using EORTC-QLQ-C30 and EORTC-QLQ-LC13, Health-related Quality of Life assessed by EORTC-QLQ-C30, Safety and Tolerability (AEs, SAEs, AESIs, laboratory values, vital signs, ECG, etc.), Pharmacokinetic Analyses, Health Status measured by EQ-5D-3L";"ALEX:
open, parallel, Randomized controlled trial (RCT)";2018-01-01-D-326;"ALEX:
Crizotinib"
783;Rybrevant;amivantamab;Non-small cell lung cancer (NSCLC);Lung cancer, non-small cell, EGFR exon 20 insertion mutation, after platinum-based therapy;2022-01-15;2022-07-07;2022-07-07;No;No;Rybrevant as monotherapy is indicated for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) and activating exon 20 insertion mutations of the epidermal growth factor receptor (EGFR) after failure of platinum-based therapy.;b) Adults with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) exon 20 insertion mutations after failure of platinum-based chemotherapy for whom no further chemotherapy is indicated;1.0;4.0;2.5;Best supportive care (BSC);No additional benefit;Janssen-Cilag GmbH;Valid;Valid;First indication;No;Oncology;No additional benefit;Forced expiratory volume in 1 second, asthma symptoms, exacerbations, health-related quality of life, adverse events;"Study 1:
double-blind, parallel, RCT (Randomized Controlled Trials)";2022-01-015-D-788;"Study 1:  
Placebo"
918;Lumykras;sotorasib;Non-small cell lung cancer (NSCLC);Non-small cell lung cancer, KRAS G12C mutation, ≥ 1 previous therapy;2023-02-01;2022-08-04;2023-08-03;No;Yes;Lumykras is used as monotherapy for the treatment of adults with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation in whom progression has been observed after at least one previous systemic therapy.;b) Adults with advanced non-small cell lung cancer (NSCLC) with KRAS p.G12C mutation after first-line treatment with cytotoxic chemotherapy;60.0;130.0;95.0;"- Docetaxel (only for patients with PD-L1 negative tumors) or
- pemetrexed (only for patients with PD-L1 negative tumors and except for predominantly squamous cell histology) or
- nivolumab or
- pembrolizumab (only for patients with PD-L1 expressing tumors (PD-L1 expression ≥ 1% of tumor cells)) or
- atezolizumab or
- docetaxel in combination with nintedanib (only for patients with PD-L1 negative tumors and adenocarcinoma histology)";No additional benefit;Amgen Europe B.V.;Valid;Valid;Reassessment: deadline expiration;No;Oncology;Non-quantifiable additional benefit;"Progression-Free Survival, Overall Survival, Objective Response Rate, Symptomatology and Health-Related Quality of Life (EORTC QLQ-C30; EORTC QLQ-LC13; EQ-5D-5L), Duration of Response, Time to Response, Disease Control Rate, Safety and Tolerability, Pharmacokinetics, PFS2, CNS Recurrence, PFS (Investigator-assessed), Biomarker Expression, PRO-CTCAE, FACT-G GP5, PGI-S, PGI-C, BPI-SF";"CodeBreak 200:  
Randomized, open-label, parallel, multicenter, active-controlled Phase III study";2023-02-01-D-913;CodeBreak 200: Docetaxel
278;Keytruda;pembrolizumab;Non-small cell lung cancer (NSCLC);Non-small cell lung cancer, first-line;2017-02-15;2017-08-03;2017-08-03;No;No;KEYTRUDA is indicated as monotherapy for the first-line treatment of metastatic non-small cell lung cancer (NSCLC) with PD-L1 expressing tumors (Tumor Proportion Score [TPS] ≥ 50%) without EGFR or ALK-positive tumor mutations in adults.;As area of application according to approval;4000.0;4000.0;4000.0;"Patients with ECOG performance status 0, 1 or 2:
- Cisplatin in combination with a third-generation cytostatic (vinorelbine or gemcitabine or docetaxel or paclitaxel or pemetrexed), taking into account the approval status or
- carboplatin in combination with a third-generation cytostatic (only for patients with an increased risk of cisplatin-induced side effects in the context of combination therapy or
- carboplatin in combination with nab-paclitaxel

Patients with ECOG performance status 2:
- as an alternative to platinum-based combination treatment: monotherapy with gemcitabine or vinorelbine";Considerable additional benefit;MSD Sharp & Dohme GmbH;Valid;Valid;New application area;No;Oncology;Considerable additional benefit;Progression-free survival, Overall survival, Objective response rate, Disease symptomatology, Health-related quality of life, Adverse events;"KEYNOTE 024:  
Randomized Phase III multicenter open active-controlled cross-over";2017-02-15-D-274;"KEYNOTE 024:  
Platinum-based combination chemotherapy"
224;Tagrisso;osimertinib;Non-small cell lung cancer (NSCLC);Non-small cell lung cancer, T790M-EGFR mutation;2016-03-15;2016-09-15;2016-09-15;No;No;TAGRISSO is indicated for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) and a positive epidermal growth factor receptor (EGFR) T790M mutation.;1b) Patients after pretreatment with an EGFR tyrosine kinase inhibitor - for patients for whom cytotoxic chemotherapy is not an option;560.0;2730.0;1645.0;Best supportive care (BSC);No additional benefit;AstraZeneca GmbH;Valid;Changed;First indication;No;Oncology;No additional benefit;FEV1, asthma symptoms, exacerbations, health-related quality of life, adverse events, morbidity, objective response rate (ORR), best overall response (BOR), progression-free survival (PFS), safety, AEs, SAEs, treatment discontinuations due to AEs, AEs with CTCAE grade ≥3, AEs with a frequency of ≥10%, exploratory endpoints, health-related quality of life and patient-reported symptoms, safety/tolerability, ORR, overall survival, progression-free survival, disease control rate, quality of life, symptomatology;"Study 1:  
Randomized Controlled Trial (RCT), double-blind, parallel";2016-03-15-D-219;"Study 1:  
Placebo"
1117;Tevimbra;tislelizumab;Non-small cell lung cancer (NSCLC);Non-small cell lung cancer (NSCLC), non-squamous, PD-L1 expression ≥ 50% of tumor cells (TC), first-line, combination with pemetrexed and platinum-based chemotherapy;2025-01-01;2025-06-15;2025-06-15;No;No;Not specified (assessment in progress);;;;;;;BeiGene Germany GmbH;In progress;In progress;New application area;No;Oncology;;;;;
460;Vizimpro;dacomitinib;Non-small cell lung cancer (NSCLC);Non-small cell lung cancer, EGFR mutation, first-line;2019-05-01;2019-10-17;2019-10-17;No;No;Vizimpro as monotherapy is used for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating EGFR mutations (epidermal growth factor receptor, EGFR).;b) Adult patients with first-line treatment of locally advanced or metastatic NSCLC with activating EGFR mutations other than L858R or del 19;100.0;300.0;200.0;"Patient-specific therapy depending on the activating EGFR mutation with a choice of:
- afatinib, gefitinib, erlotinib, osimertinib
- cisplatin in combination with a third-generation cytostatic (vinorelbine or gemcitabine or docetaxel or paclitaxel or pemetrexed)
- carboplatin in combination with a third-generation cytostatic agent (vinorelbine or gemcitabine or docetaxel or paclitaxel or pemetrexed)
- carboplatin in combination with nab-paclitaxel
and
- monotherapy with gemcitabine or vinorelbine (only for patients with ECOG performance status 2 as an alternative to platinum-based combination treatment).";No additional benefit;Pfizer Pharma GmbH;Valid;Valid;First indication;No;Oncology;No additional benefit;Progression-free survival (PFS), Overall survival (OS), Best overall response (BOR), Time to deterioration regarding pain (in chest or arm/shoulder), dyspnea, fatigue, or cough, Health-related quality of life measured by the EORTC QLQ-C30, Health status measured by the EQ-5D VAS, Overall survival at 30 months (OS30m), Duration of response (DoR), Time to treatment failure (TTF), Restricted mean survival time (RMST) for progression-free survival (PFS), Restricted mean survival time (RMST) for overall survival (OS), Safety and tolerability;"ARCHER 1050 (A7471050):  
Randomized Controlled Trial (RCT), open-label, active-controlled, parallel, multinational, multicenter, Phase III study";2019-05-01-D-442;"ARCHER 1050 (A7471050):
Gefitinib"
285;Alecensa;alectinib;Non-small cell lung cancer (NSCLC);Non-small cell lung cancer, ALK+, after crizotinib pre-therapy;2017-05-01;2017-10-19;2017-10-19;No;No;Alecensa is used as monotherapy for the treatment of anaplastic lymphoma kinase (ALK)-positive, advanced non-small cell lung cancer (NSCLC) in adult patients who have previously been treated with crizotinib.;b) Patients for whom treatment with docetaxel or pemetrexed or ceritinib is not an option;40.0;250.0;145.0;Best supportive care (BSC);No additional benefit;Roche Pharma AG;Valid;Valid;First indication;No;Oncology;Minor additional benefit;Overall Response Rate (assessed by IRC), Overall Response Rate (assessed by Investigator), Disease Control Rate (DCR), Duration of Response (DOR), Progression-Free Survival (PFS), Overall Survival (OS), Tolerability (AEs, SAEs, AEs leading to study discontinuation, AESI), Health-Related Quality of Life assessed by EORTC QLQ-C30/LC13, CNS Response (CORR, CDOR, CPR), Overall Response Rate (assessed by IRC) in patients pretreated with chemotherapy, Overall Response Rate (assessed by IRC) in treatment‐naïve patients, Progression-Free Survival (assessed by IRC and investigator), Progression-Free Survival, Objective Response Rate (ORR), Duration of Response (DR), Time to Response (TTR), 6-Month and 1-Year Survival Probability, Adverse Events, Patient Reported Outcomes (PRO) (Quality of Life, Lung Cancer-Specific Symptoms, Health Status), Safety/Tolerability;"NP28673:
Open-label, single-arm Phase I/II study in three parts

NP28761:
Open-label, single-arm Phase I/II study in adult patients with locally advanced (AJCC Stage IIIB) or metastatic (AJCC Stage IV) ALK-positive NSCLC who were treated after progression on Crizotinib";2017-05-01-D-281;"NP28673:
Pemetrexed + Carboplatin
Pemetrexed + Cisplatin

NP28761:
Crizotinib"
770;Gavreto;pralsetinib;Non-small cell lung cancer (NSCLC);Non-small cell lung cancer, non-small cell, RET-fusion+;2021-12-15;2022-06-16;2022-06-16;No;No;Gavreto is used as monotherapy for the treatment of adult patients with rearranged-during-transfection (RET) fusion-positive advanced non-small cell lung cancer (NSCLC) who have not previously been treated with a RET inhibitor.;d) Adults with RET fusion-positive, advanced non-small cell lung cancer (NSCLC) after first-line treatment with cytotoxic chemotherapy;20.0;80.0;50.0;"- Docetaxel (only for patients with PD-L1 negative tumors) or
- pemetrexed (only for patients with PD-L1 negative tumors and except for predominantly squamous cell histology) or
- nivolumab or
- pembrolizumab (only for patients with PD-L1 expressing tumors, PD-L1 expression ≥ 1% of tumor cells) or
- atezolizumab or
- docetaxel in combination with nintedanib (only for patients with PD-L1 negative tumors and adenocarcinoma histology)";No additional benefit;Roche Pharma AG;Valid;Valid;First indication;No;Oncology;No additional benefit;Determination of the MTD, Determination of the RP2D, Evaluation of safety and tolerability, Determination of the ORR, Pharmacokinetics, Pharmacodynamics, Antineoplastic activity, DOR, CBR, DCR, PFS, OS, Changes in patient-reported outcomes;"ARROW:  
Multicenter, international, single-arm, open-label Phase I/II study investigating the safety, pharmacokinetics, pharmacodynamics, and efficacy of Pralsetinib in adult patients with RET-fusion-positive non-small cell lung cancer (NSCLC) and other RET-altered solid tumors.";2021-12-15-D-757;Since this is a single-arm study, there is no direct comparison group or study comparator.
259;Keytruda;pembrolizumab;Non-small cell lung cancer (NSCLC);Non-small cell lung cancer, after prior chemotherapy;2016-08-15;2017-02-02;2017-02-02;No;No;KEYTRUDA is indicated for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) with PD-L1-expressing tumors in adults who have previously undergone chemotherapy. Patients with EGFR- or ALK-positive tumor mutations should have received an approved therapy for these mutations prior to treatment with KEYTRUDA.;1) Patients for whom therapy with docetaxel, pemetrexed or nivolumab is indicated;3900.0;10800.0;7350.0;"- Docetaxel or
- pemetrexed or
- nivolumab
(Pemetrexed: except for predominantly squamous histology)";Considerable additional benefit;MSD Sharp & Dohme GmbH;Valid;Valid;New application area;No;Oncology;Considerable additional benefit;Overall survival, Progression-free survival, Disease symptomatology, Health-related quality of life, Adverse events;"KEYNOTE 010:
active-controlled, multicenter, open-label, parallel, Phase II/III, RCT (Randomized Controlled Trial)";2016-08-15-D-251;"KEYNOTE 010:  
Docetaxel"
314;Tecentriq;atezolizumab;Non-small cell lung cancer (NSCLC);Non-small cell lung cancer, after prior chemotherapy;2017-10-01;2018-03-16;2018-03-16;No;No;Tecentriq as monotherapy is used in adult patients for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) after prior chemotherapy. Patients with activating EGFR mutations or ALK-positive tumor mutations should have already received therapy targeting these mutations prior to treatment with Tecentriq.;b) Atezolizumab as monotherapy for the treatment of adult patients with advanced non-small cell lung cancer for whom therapy with docetaxel, pemetrexed, nivolumab and pembrolizumab is not indicated after prior chemotherapy;12900.0;19200.0;16050.0;Best supportive care (BSC);No additional benefit;Roche Pharma AG;Valid;Valid;First indication;No;Oncology;Considerable additional benefit;Overall Survival, Progression-Free Survival (RECIST v1.1), Progression-Free Survival (modified RECIST v1.1), Objective Response Rate (RECIST v1.1), Objective Response Rate (modified RECIST v1.1), Duration of Response (RECIST v1.1), Duration of Response (modified RECIST v1.1), EORTC QLQ-C30, EORTC QLQ-LC13, EQ-5D-3L, Adverse Events;"GO28915 (OAK):  
open, parallel, Randomized Controlled Trial (RCT)";2017-10-01-D-313;"GO28915 (OAK):  
Docetaxel"
264;Zykadia;ceritinib;Non-small cell lung cancer (NSCLC);Non-small cell lung cancer, ALK+, after crizotinib pre-therapy;2016-10-01;2015-12-17;2017-03-16;No;Yes;Zykadia is used in adult patients for the treatment of advanced, anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) who have been pretreated with crizotinib.;2) Patients for whom treatment with docetaxel or pemetrexed is not an option;20.0;110.0;65.0;Best supportive care (BSC);No additional benefit;Novartis Pharma GmbH;Valid;Valid;Reassessment: deadline expiration;No;Oncology;Considerable additional benefit;Progression-free survival, Overall survival, Tumor response (ORR, DCR, time to first response, duration of response), Intracranial tumor response (OIRR, IDCR, duration of intracranial response), Safety, Patient-reported outcomes: EORTC-QLQ-C30, EORTC-QLQ-LC13, LCSS, EQ-5D;"ASCEND-5:  
Randomized controlled Phase III study open parallel";2016-10-01-D-259;"ASCEND-5:  
Chemotherapy"
460;Vizimpro;dacomitinib;Non-small cell lung cancer (NSCLC);Non-small cell lung cancer, EGFR mutation, first-line;2019-05-01;2019-10-17;2019-10-17;No;No;Vizimpro as monotherapy is used for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating EGFR mutations (epidermal growth factor receptor, EGFR).;a) Adult patients with first-line treatment of locally advanced or metastatic NSCLC with the activating EGFR mutations L858R1 or del 192;790.0;1910.0;1350.0;"- Afatinib or
- gefitinib or
- erlotinib or
- osimertinib";No additional benefit;Pfizer Pharma GmbH;Valid;Valid;First indication;No;Oncology;No additional benefit;Progression-free survival (PFS), Overall survival (OS), Best overall response (BOR), Time to deterioration regarding pain (in chest or arm/shoulder), dyspnea, fatigue, or cough, Health-related quality of life measured by the EORTC QLQ-C30, Health status measured by the EQ-5D VAS, Overall survival at 30 months (OS30m), Duration of response (DoR), Time to treatment failure (TTF), Restricted mean survival time (RMST) for progression-free survival (PFS), Restricted mean survival time (RMST) for overall survival (OS), Safety and tolerability;"ARCHER 1050 (A7471050):
active controlled, multicenter, multinational, parallel, Phase III study, Randomized Controlled Trial (RCT), unblinded";2019-05-01-D-442;"ARCHER 1050 (A7471050):
Gefitinib"
186;Nivolumab BMS/Opdivo;nivolumab;Non-small cell lung cancer (NSCLC);Non-small cell lung carcinoma, squamous cell histology, after prior chemotherapy;2015-08-15;2016-02-04;2016-02-04;Yes;No;OPDIVO is indicated for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) with squamous cell histology after prior chemotherapy in adults.;2) Patients for whom treatment with docetaxel is not indicated;500.0;800.0;650.0;Best supportive care (BSC);No additional benefit;Bristol-Myers Squibb GmbH & Co. KGaA;Valid;Valid;New application area;No;Oncology;Considerable additional benefit;Overall Survival (OS), Index value of disease-related symptoms according to LCSS, Health-related quality of life according to LCSS, Generic quality of life according to EQ-5D, Safety and tolerability (AEs);"CA209-017:
open, parallel, RCT (Randomized Controlled Trial)";2015-08-15-D-184;"CA209-017:  
Docetaxel"
44;Xalkori;crizotinib;Non-small cell lung cancer (NSCLC);Non-small cell lung cancer, ALK+, pre-treated patients;2012-11-15;2013-05-02;2013-05-02;No;No;XALKORI is used in adults for the treatment of pretreated anaplastic lymphoma kinase (ALK)-positive, advanced non-small cell lung cancer (NSCLC).;a) Patients for whom chemotherapy is indicated.;340.0;340.0;340.0;"- Docetaxel or
- Pemetrexed for the treatment of patients for whom chemotherapy is indicated (these can particularly be patients with ECOG performance status 0, 1, and possibly 2).";Considerable additional benefit;Pfizer Pharma GmbH;Repealed;Repealed;First indication;No;Oncology;Considerable additional benefit;Progression-Free Survival, Overall Survival, Objective Response Rate (ORR), Duration of Response (DR), Time to Response (TTR), Disease Control Rate (DCR), 6-Month Survival Probability, 1-Year Survival Probability, Adverse Events, Patient Reported Outcomes (PRO);"NCT00932893:  
RCT (Randomized Controlled Trial), open, multicenter, multinational, two-arm, Phase III, efficacy and safety study";2012-11-15-D-040;"NCT00932893:  
Docetaxel, Pemetrexed"
867;Tabrecta;capmatinib;Non-small cell lung cancer (NSCLC);Non-small cell lung cancer, METex14 skipping mutation, pre-treated patients;2022-08-15;2023-02-02;2023-02-02;No;No;Tabrecta as monotherapy is used to treat adult patients with advanced non-small cell lung cancer (NSCLC) with alterations leading to METex14 skipping (exon 14 skipping in the mesenchymal-epithelial transition factor gene) who require systemic therapy following treatment with immunotherapy and/or platinum-based chemotherapy.;a) Adults with advanced non-small cell lung cancer (NSCLC) with METex14 skipping (exon 14 skipping in the mesenchymal-epithelial transition factor gene) mutation after first-line therapy with a PD-1/PD-L1 antibody as monotherapy;80.0;130.0;105.0;"- Cisplatin in combination with a third-generation cytostatic (vinorelbine or gemcitabine or docetaxel or paclitaxel or pemetrexed (except in the case of predominantly squamous histology)) or
- carboplatin in combination with a third-generation cytostatic agent (vinorelbine or gemcitabine or docetaxel or paclitaxel or pemetrexed (except for predominantly squamous histology)) or
- carboplatin in combination with nab-paclitaxel or
- monotherapy with gemcitabine or vinorelbine (only for patients with ECOG performance status 2 as an alternative to platinum-based combination treatment)";No additional benefit;Novartis Pharma GmbH;Valid;Valid;First indication;No;Oncology;No additional benefit;Overall survival (OS), Progression-free survival (PFS), Overall response rate (ORR), Time to CNS progression (CNSprog), Time to treatment discontinuation due to adverse events (TDAE), Unplanned or prolonged hospitalization (upHOSP), Unplanned or prolonged hospitalization or death (upHOSP + D);"GEOMETRY mono-1 Study (Capmatinib): International data from the GEOMETRY mono-1 study are compared with retrospectively collected patient data from the nNGM cohort, which represents the German standard of care (SoC) or the defined appropriate comparison therapy (zVT).
RECAP: Non-randomized, comparative study investigating the efficacy and safety of Capmatinib in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with METex14-skipping mutation. The study design includes prospectively collected data in the Capmatinib group and retrospective real-world data in accordance with G-BA guidelines.";2022-08-15-D-855;The comparator arm in the RECAP study is based on patient data from the nNGM cohort, which represents the German standard of care (SoC) as well as the defined appropriate comparison therapy (zVT). The patients were selected according to strict, G-BA-compliant inclusion and exclusion criteria and serve as an external control arm compared to the Capmatinib group of the GEOMETRY mono-1 study.
87;Giotrif;afatinib;Non-small cell lung cancer (NSCLC);Non-small cell lung cancer, EGFR mutation, EGFR-TKI-naïve patients;2013-11-15;2014-05-08;2014-05-08;No;No;Giotrif® as monotherapy is used for the treatment of EGFR-TKI-naive adult patients with locally advanced and/or metastatic non-small cell lung cancer (NSCLC) with activating EGFR mutations.;1a) Previously untreated patients with ECOG performance status 0 or 1, patient group with EGFR mutation Del19;320.0;2180.0;1250.0;"- Gefitinib or erlotinib or
- cisplatin in combination with a third-generation cytostatic (Vinorelbine, Gemcitabine, Docetaxel, Paclitaxel, Pemetrexed) considering the respective approved indication";Considerable additional benefit;Boehringer Ingelheim Pharma GmbH & Co. KG;Repealed;Repealed;First indication;No;Oncology;Considerable additional benefit;Progression-free survival, Overall Survival, Objective Response Rate, Symptomatology (EORTC QLQ-C30, EORTC QLQ-LC13), Health-related quality of life (EORTC QLQ-C30, EQ-5D), Adverse events;"LUX-Lung 3 (NCT00949650):  
Randomized controlled trial (RCT), open-label, parallel, active-controlled, phase III study, multicenter multinational

LUX-Lung 6 (NCT01121393):  
RCT, open-label, parallel, active-controlled, phase III study, multicenter multinational";2013-11-15-D-082;"NCT00949650:  
Cisplatin + Pemetrexed  

NCT01121393:  
Cisplatin + Gemcitabine"
304;Zykadia;ceritinib;Non-small cell lung cancer (NSCLC);Non-small cell lung cancer, ALK+, first-line;2017-08-01;2018-02-01;2018-02-01;No;No;Zykadia is used as monotherapy in adult patients for the first-line treatment of advanced, anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC).;As area of application according to approval;350.0;850.0;600.0;Crizotinib;No additional benefit;Novartis Pharma GmbH;Valid;Valid;New application area;No;Oncology;No additional benefit;Progression-free survival, Overall survival, Overall response rate, Disease control rate, Time to first response, Duration of response, Overall intracranial response rate, Intracranial disease control rate, Intracranial clinical benefit rate, Duration of intracranial response, Safety, EORTC-QLQ-C30, EORTC-QLQ-LC13, LCSS, EQ-5D;"ASCEND-4:  
Randomized controlled Phase III study open parallel";2017-08-01-D-296;"ASCEND-4:  
Carboplatin + Pemetrexed  
Cisplatin + Pemetrexed"
942;Tremelimumab AstraZeneca;tremelimumab;Non-small cell lung cancer (NSCLC);Non-small cell lung cancer, EGFR/ALK-negative, first-line, combination with durvalumab and platinum-based chemotherapy;2023-04-01;2023-10-05;2023-10-05;No;No;Tremelimumab AstraZeneca in combination with durvalumab and platinum-based chemotherapy is indicated in adults for the first-line treatment of metastatic non-small cell lung cancer (NSCLC) without sensitizing EGFR mutations or ALK-positive mutations.;a) Adults with metastatic NSCLC with PD-L1 expression ≥ 50% without genomic EGFR or ALK tumor mutations, first-line therapy;3860.0;6850.0;5355.0;"- Pembrolizumab as monotherapy or
- atezolizumab as monotherapy or
- cemiplimab as monotherapy or
- nivolumab in combination with ipilimumab and 2 cycles of platinum-based chemotherapy (only for patients with ECOG PS 0-1) or
- pembrolizumab in combination with carboplatin and either paclitaxel or nab-paclitaxel (only for patients with ECOG PS 0-1 and squamous NSCLC) or
- pembrolizumab in combination with pemetrexed and platinum-containing chemotherapy (only for patients with ECOG PS 0-1 and non-squamous NSCLC) or
- atezolizumab in combination with bevacizumab, paclitaxel and carboplatin (only for patients with ECOG PS 0-1 and non-squamous NSCLC) or
- atezolizumab in combination with nab-paclitaxel and carboplatin (only for patients with ECOG PS 0-1 and non-squamous NSCLC)";No additional benefit;AstraZeneca GmbH;Valid;Valid;First indication;No;Oncology;No additional benefit;Overall survival, Progression-free survival, Objective response rate, Progression-free survival 2, EORTC QLQ-C30, EORTC QLQ-LC13, EQ-5D Visual Analog Scale, Patient Global Impression of Change, Adverse events;"POSEIDON 1:  
Randomized, controlled, open-label, multicenter, global Phase III study with allocation ratio of 1:1:1";2023-04-01-D-923;"POSEIDON 1:  
CTx (Platinum-based chemotherapy)"
176;Zykadia;ceritinib;Non-small cell lung cancer (NSCLC);Non-small cell lung cancer, ALK+, after crizotinib pre-therapy;2015-07-01;2015-12-17;2015-12-17;No;No;Zykadia is used in adult patients for the treatment of advanced, anaplastic lymphoma kinase (ALK)-positive, non-small cell lung cancer (NSCLC), who have been pretreated with crizotinib.;2) Patients for whom treatment with Docetaxel or Pemetrexed is not an option;20.0;110.0;65.0;Best supportive care (BSC);No additional benefit;Novartis Pharma GmbH;Repealed;Repealed;First indication;No;Oncology;No additional benefit;Determination of the MTD of Ceritinib, Safety and tolerability, Pharmacokinetics with single and multiple dosing, Antiproliferative activity, Objective response rate (ORR), Progression-free survival (PFS), Overall survival, Duration of response (DOR)*, Time to response (TTR)*, Disease control rate (DCR)*, 6-month and 1-year survival probability, Adverse events, Patient-reported outcomes (PRO) (quality of life, lung cancer-specific symptoms, health status);"PROFILE 1007:  
Open, multicenter, randomized, controlled study (Phase III)";2015-07-01-D-171;PROFILE 1007: Historical Comparison: Docetaxel vs. Pemetrexed
209;Xalkori;crizotinib;Non-small cell lung cancer (NSCLC);Non-small cell lung cancer, ALK+, first-line;2016-01-01;2016-06-16;2016-06-16;No;No;XALKORI is used in adults for the first-line treatment of anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC).;As area of application according to approval;300.0;900.0;600.0;"- Cisplatin in combination with a third-generation cytostatic (vinorelbine or gemcitabine or docetaxel or paclitaxel or pemetrexed), taking into account the approval status or
- carboplatin in combination with a third-generation cytostatic (only for patients with an increased risk of cisplatin-induced side effects as part of combination therapy
Patients with ECOG performance status 2:
- as an alternative to platinum-based combination treatment: monotherapy with gemcitabine or vinorelbine";Considerable additional benefit;Pfizer Pharma GmbH;Valid;Valid;New application area;No;Oncology;Considerable additional benefit;Progression-Free Survival, Overall Survival, Objective Response Rate (ORR), Duration of Response (DR), Time to Response (TTR), Disease Control Rate (DCR), 6-Month and 1-Year Survival Probability, Adverse Events, Patient Reported Outcomes (PRO) (Quality of Life, Lung Cancer-Specific Symptoms, Health Status), Safety/Tolerability;Randomized Controlled Trial (RCT), efficacy and safety study, multicenter, multinational, open, Phase III, two-arm;2016-01-01-D-205;Chemotherapy (platinum-based combination treatment with pemetrexed)
630;Yervoy;ipilimumab;Non-small cell lung cancer (NSCLC);Non-small cell lung cancer, first-line, combination with nivolumab and platinum-based chemotherapy;2020-12-15;2021-06-03;2021-06-03;No;No;Yervoy is indicated in combination with nivolumab and 2 cycles of platinum-based chemotherapy for the first-line treatment of metastatic non-small cell lung cancer (NSCLC) in adults whose tumors do not have a sensitizing EGFR mutation or ALK translocation.;"b) Adult patients with metastatic non-small cell lung cancer (NSCLC) with a Tumor Proportion Score [TPS] of < 50% (PD-L1 expression) and without EGFR mutations or ALK translocations; first-line treatment";10630.0;11500.0;11065.0;"- Cisplatin in combination with a third-generation cytostatic (vinorelbine or gemcitabine or docetaxel or paclitaxel or pemetrexed (except in the case of predominantly squamous histology)) or
- carboplatin in combination with a third-generation cytostatic agent (vinorelbine or gemcitabine or docetaxel or paclitaxel or pemetrexed (except for predominantly squamous histology)) or
- carboplatin in combination with nab-paclitaxel or
- pembrolizumab in combination with pemetrexed and platinum-containing chemotherapy (only for patients with non-squamous histology) or
- pembrolizumab in combination with carboplatin and either paclitaxel or nab-paclitaxel (only for patients with squamous histology)";Minor additional benefit;Bristol-Myers Squibb Pharma EEIG;Valid;Valid;New application area;No;Oncology;Minor additional benefit;Overall Survival (OS), Disease-related symptoms according to LCSS, Health-related quality of life according to LCSS, Health status according to EQ-5D-VAS, Adverse Events;"CA209-9LA:  
open, parallel, RCT (Randomized Controlled Trial)";2020-12-15-D-629;"CA209-9LA:  
Platinum-based chemotherapy"
227;Portrazza;necitumumab;Non-small cell lung cancer (NSCLC);Non-small cell lung cancer;2016-04-01;2016-09-15;2016-09-15;No;No;Portrazza is indicated in combination with gemcitabine and cisplatin chemotherapy for the treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor (EGFR)-expressing squamous non-small cell lung cancer who have not previously received chemotherapy for this stage of the disease.;As area of application according to approval;6300.0;7700.0;7000.0;Cisplatin in combination with a third-generation cytostatic drug (vinorelbine or gemcitabine or docetaxel or paclitaxel), taking into account the approval status.;No additional benefit;Lilly Deutschland GmbH;Valid;Valid;First indication;No;Oncology;No additional benefit;Overall Survival (OS), Progression-Free Survival (PFS), Endpoints for disease symptomatology (LCSS), Endpoints for health-related quality of life (EQ-5D, LCSS), Safety endpoints;"SQUIRE:
2-arm parallel, international, multicenter, open, RCT (Randomized controlled trial)";2016-04-01-D-221;"SQUIRE:  
Gemcitabine + Cisplatin"
977;Opdivo;nivolumab;Non-small cell lung cancer (NSCLC);Non-small cell lung cancer, PD-L1 expression ≥ 1%, neoadjuvant therapy, combination with platinum-based chemotherapy;2023-08-01;2024-02-01;2024-02-01;No;No;Opdivo is indicated in combination with platinum-based chemotherapy for the neoadjuvant treatment of resectable non-small cell lung cancer with tumor cell PD-L1 expression ≥ 1 % in adults at high risk of recurrence.;"Adults with resectable non-small cell lung cancer with tumor cell PD-L1 expression ≥ 1% with high risk of recurrence; neoadjuvant therapy";110.0;990.0;550.0;"Patient-specific therapy with selection of
• preoperative (neoadjuvant) systemic chemotherapy with selection of
  - cisplatin in combination with a third-generation cytostatic (vinorelbine or gemcitabine or docetaxel or paclitaxel or pemetrexed) and
  - carboplatin in combination with a third-generation cytostatic (vinorelbine or gemcitabine or docetaxel or paclitaxel or pemetrexed) and
• simultaneous radiochemotherapy with platinum-based (cisplatin or carboplatin) combination chemotherapy
taking into account the tumor stage, the tumor histology, the presence of a Pancoast tumor and the achievability of an R0 resection, as well as the prerequisites for the use of carboplatin.";Non-quantifiable additional benefit;Bristol-Myers Squibb GmbH & Co. KGaA;Valid;Valid;New application area;No;Oncology;Non-quantifiable additional benefit;Pathologic Complete Response (pCR) according to BIPR, Event-Free Survival (EFS) according to BICR, Overall Survival (OS), Health status according to EQ-5D VAS, Adverse Events;"CA209-816:  
Randomized controlled trial (RCT), open-label, parallel adults with resectable non-small cell lung cancer (NSCLC) stage IB (≥ 4 cm) – IIIA (according to the International Association for the Study of Lung Cancer (IASLC) 7th edition)";2023-08-01-D-966;"CA209-816:  
Chemotherapy"
248;Xalkori;crizotinib;Non-small cell lung cancer (NSCLC);Non-small cell lung cancer, ALK+, pre-treated patients;2016-07-01;2013-05-02;2016-12-15;No;Yes;XALKORI is used in adults for the treatment of previously treated anaplastic lymphoma kinase (ALK)-positive, advanced non-small cell lung cancer (NSCLC).;b) Patients for whom chemotherapy is not indicated;140.0;140.0;140.0;Best supportive care (BSC) for the treatment of patients for whom chemotherapy is not indicated (these may be in particular patients with ECOG performance status 4, 3 and possibly 2).;No additional benefit;Pfizer Pharma GmbH;Valid;Valid;Reassessment: deadline expiration;No;Oncology;Considerable additional benefit;Progression-Free Survival (PFS), Overall Survival (OS), Objective Response Rate (ORR), Duration of Response (DR), Time to Response (TTR), Disease Control Rate (DCR), 6-Month and 1-Year Survival Probability, Adverse Events, Patient-Reported Outcomes (PRO);"PROFILE1007:  
efficacy and safety study, multicenter, multinational, open, Phase III, RCT (Randomized Controlled Trial), two-arm";2016-07-01-D-240;"PROFILE1007:  
Docetaxel, Pemetrexed"
222;Cyramza;ramucirumab;Non-small cell lung cancer (NSCLC);Non-small cell lung cancer;2016-03-01;2016-09-01;2016-09-01;No;No;Ramucirumab (Cyramza®) is indicated in combination with docetaxel for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer with tumor progression after platinum-containing chemotherapy.;As area of application according to approval;5900.0;15400.0;10650.0;"- Docetaxel or
- pemetrexed (pemetrexed: except for predominantly squamous histology) or
- gefitinib or erlotinib (only for patients with activating EGFR mutations who have not yet been pretreated with afatinib, gefitinib or erlotinib) or
- crizotinib (only for patients with activating ALK mutations who have not yet been pretreated with crizotinib)";No additional benefit;Lilly Deutschland GmbH;Valid;Valid;New application area;No;Oncology;No additional benefit;Overall survival, Progression-free survival, Objective response rate, Quality of life (EORTC QLQ-C30, EQ-5D), Safety;"RAISE (I4T-MCJVBB):  
RCT (Randomized Controlled Trial), double-blind, parallel";2016-03-01-D-217;"RAISE (I4T-MCJVBB):  
Placebo + FOLFIRI"
846;Retsevmo;selpercatinib;Non-small cell lung cancer (NSCLC);Non-small cell lung cancer, RET-fusion+, first-line;2022-07-01;2022-12-15;2022-12-15;No;No;"Retsevmo as monotherapy is used to treat adults with:
- advanced RET fusion-positive non-small cell lung cancer (NSCLC) who have not previously been treated with an RET inhibitor.";"b) Adults with advanced RET fusion-positive non-small cell lung cancer (NSCLC) with PD-L1 expression < 50% of tumor cells; first-line treatment";85.0;220.0;153.0;"- Cisplatin in combination with a third-generation cytostatic (vinorelbine or gemcitabine or docetaxel or paclitaxel or pemetrexed (except in the case of predominantly squamous histology)) or
- carboplatin in combination with a third-generation cytostatic agent (vinorelbine or gemcitabine or docetaxel or paclitaxel or pemetrexed (except in the case of predominantly squamous histology)) or
- carboplatin in combination with nab-paclitaxel or
- pembrolizumab in combination with pemetrexed and platinum-containing chemotherapy (only for patients without EGFR- or ALK-positive tumor mutations and with non-squamous histology) or
- pembrolizumab in combination with carboplatin and either paclitaxel or nab-paclitaxel (only for squamous cell histology) or
- monotherapy with gemcitabine or vinorelbine (only for patients with ECOG performance status 2 as an alternative to platinum-based combination treatment)";No additional benefit;Lilly Deutschland GmbH;Valid;Valid;New application area;No;Oncology;No additional benefit;Determination of the MTD and the recommended Phase 2 dose, Assessment of safety and tolerability, Characterization of the pharmacokinetic profile, Determination of the objective response rate, Determination of the objective response rate (confirmed by the IRC), Determination of the objective response rate (confirmed by the investigator), Objective response rate pertaining to the CNS, Best overall response, Duration of response (overall and pertaining to the CNS), Time to response, Disease control rate, Progression-free survival, Overall survival;"LIBRETTO-001:
International, multicenter, open Phase 1/2 study with dose escalation (3+3 design) and dose expansion phases";2022-07-01-D-832;LIBRETTO-001: No direct comparison arm is available, as the study is designed as a single-arm investigation.
87;Giotrif;afatinib;Non-small cell lung cancer (NSCLC);Non-small cell lung cancer, EGFR mutation, EGFR-TKI-naïve patients;2013-11-15;2014-05-08;2014-05-08;No;No;Giotrif® as monotherapy is used for the treatment of EGFR-TKI-naive adult patients with locally advanced and/or metastatic non-small cell lung cancer (NSCLC) with activating EGFR mutations.;1c) Previously untreated patients with ECOG performance status 0 or 1, patient group with other EGFR mutations;90.0;620.0;355.0;"- Gefitinib or erlotinib or
- cisplatin in combination with a third-generation cytostatic (Vinorelbine, Gemcitabine, Docetaxel, Paclitaxel, Pemetrexed) considering the respective approved indication";Less benefit;Boehringer Ingelheim Pharma GmbH & Co. KG;Repealed;Repealed;First indication;No;Oncology;Considerable additional benefit;Progression-free survival, Overall Survival, Objective Response Rate, Symptomatology (EORTC QLQ-C30, EORTC QLQ-LC13), Health-related quality of life (EORTC QLQ-C30, EQ-5D), Adverse events;"LUX-Lung 3 (NCT00949650):
active controlled, multicenter, multinational, open, parallel, Phase III study, Randomized Controlled Trial (RCT)

LUX-Lung 6 (NCT01121393):
active controlled, multicenter, multinational, open, parallel, Phase III study, Randomized Controlled Trial (RCT)";2013-11-15-D-082;"NCT00949650:  
Cisplatin + Pemetrexed  

NCT01121393:  
Cisplatin + Gemcitabine"
1173;Lazcluze;lazertinib;Non-small cell lung cancer (NSCLC);Non-small cell lung carcinoma, EGFR exon 19 deletions or exon 21 substitution mutations (L858R), in combination with amivantamab;2025-02-15;2025-08-01;2025-08-01;No;No;;;;;;;;Janssen-Cilag GmbH;In progress;In progress;First indication;No;Oncology;;;;;
224;Tagrisso;osimertinib;Non-small cell lung cancer (NSCLC);Non-small cell lung cancer, T790M-EGFR mutation;2016-03-15;2016-09-15;2016-09-15;No;No;TAGRISSO is indicated for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) and a positive epidermal growth factor receptor (EGFR) T790M mutation.;3) Patients previously treated with platinum-based chemotherapy and a de novo positive T790M mutation;5.0;50.0;28.0;"− Docetaxel or pemetrexed
(Pemetrexed: except in predominantly squamous histology
or
− gefitinib or erlotinib
(only for patients with activating EGFR mutations who have not previously been treated with gefitinib or erlotinib)
Patients for whom therapy with docetaxel, pemetrexed, gefitinib and erlotinib is not indicated:
- Best supportive care (BSC)";No additional benefit;AstraZeneca GmbH;Valid;Changed;First indication;No;Oncology;No additional benefit;FEV1, asthma symptoms, exacerbations, health-related quality of life, adverse events, morbidity, objective response rate (ORR), best overall response (BOR), progression-free survival (PFS), safety, AEs, SAEs, treatment discontinuations due to AEs, AEs with CTCAE grade ≥3, AEs with a frequency of ≥10%, exploratory endpoints, health-related quality of life and patient-reported symptoms, safety/tolerability, ORR, overall survival, progression-free survival, disease control rate, quality of life, symptomatology;"Study 1:  
Randomized Controlled Trial (RCT), double-blind, parallel";2016-03-15-D-219;"Study 1:  
Placebo"
1136;Tecentriq;atezolizumab;Non-small cell lung cancer (NSCLC);Non-small cell lung cancer, PD-L1 expression ≥ 50%, adjuvant therapy after resection and chemotherapy;2024-10-01;2023-01-05;2025-03-20;No;Yes;Tecentriq as monotherapy is used for the adjuvant treatment of NSCLC after complete resection and platinum-based chemotherapy in adult patients at high risk of recurrence whose tumors express PD-L1 on ≥ 50% of tumor cells (TC) and who do not have EGFR-mutated or ALK-positive NSCLC.;As area of application according to approval;700.0;890.0;795.0;Watchful waiting;Considerable additional benefit;Roche Pharma AG;Valid;Valid;Reassessment: deadline expiration;No;Oncology;Considerable additional benefit;DFS (investigator-assessed), Disease‐free survival in stage II‐IIIA with PD‐L1 ≥1% (SP263), Disease‐free survival in stage II‐IIIA, Disease‐free survival in the ITT population, Overall survival, DFS rate after 3 and 5 years, Disease‐free survival in PD‐L1 TC ≥50% (SP263) in the stage II‐IIIA subpopulation, Adverse events, Immunogenicity;"IMpower010:  
Phase III, randomized controlled trial, open, parallel, multicenter";2024-10-01-D-1118;"IMpower010:  
Watchful Waiting"
495;Tecentriq;atezolizumab;Non-small cell lung cancer (NSCLC);"NSCLC, non-squamous, first-line, combination with nab-paclitaxel and carboplatin; maintenance therapy";2019-10-01;2020-04-02;2020-04-02;No;No;Tecentriq is used in combination with nab-paclitaxel and carboplatin for the first-line treatment of metastatic NSCLC with non-squamous histology in adult patients who do not have EGFR mutations or ALK-positive NSCLC.;"a) Adult patients with metastatic non-small cell lung cancer with non-squamous cell histology and a Tumor Proportion Score [TPS] of ≥ 50% (PD-L1 expression) and without EGFR- or ALK-positive tumor mutations; first-line therapy";2320.0;2640.0;2480.0;Pembrolizumab as monotherapy;No additional benefit;Roche Pharma AG;Valid;Valid;New application area;No;Oncology;No additional benefit;Overall survival, Progression-free survival (RECIST v1.1), Objective response rate (RECIST v1.1), Duration of response (RECIST v1.1), EORTC QLQ-C30, EORTC QLQ-LC13, EQ-5D VAS, Adverse events;"IMpower130:  
active-controlled, multicenter, open, parallel, Phase III, Randomized controlled trial (RCT)";2019-10-01-D-486;"IMpower130:  
Carboplatin + nab (Nanoparticle albumin bound)-Paclitaxel"
770;Gavreto;pralsetinib;Non-small cell lung cancer (NSCLC);Non-small cell lung cancer, non-small cell, RET-fusion+;2021-12-15;2022-06-16;2022-06-16;No;No;Gavreto is used as monotherapy for the treatment of adult patients with rearranged-during-transfection (RET) fusion-positive advanced non-small cell lung cancer (NSCLC) who have not previously been treated with a RET inhibitor.;"e) Adults with RET fusion-positive, advanced non-small cell lung cancer (NSCLC); after first-line therapy with a PD-1/PD-L1 antibody in combination with platinum-containing chemotherapy or after sequential therapy with a PD-1/PD-L1 antibody and platinum-containing chemotherapy";30.0;100.0;65.0;"Patient-specific therapy with selection of
- afatinib
- pemetrexed
- erlotinib
- docetaxel
- docetaxel in combination with ramucirumab
- docetaxel in combination with nintedanib
- vinorelbine
taking into account previous therapy and histology";No additional benefit;Roche Pharma AG;Valid;Valid;First indication;No;Oncology;No additional benefit;Determination of the MTD, Determination of the RP2D, Evaluation of safety and tolerability, Determination of the ORR, Pharmacokinetics, Pharmacodynamics, Antineoplastic activity, DOR, CBR, DCR, PFS, OS, Changes in patient-reported outcomes;"ARROW:  
Multicenter, international, single-arm, open-label Phase I/II study";2021-12-15-D-757;Since this is a single-arm study, there is no direct comparison arm or study comparator.
694;Tecentriq;atezolizumab;Non-small cell lung cancer (NSCLC);Non-small cell lung cancer, PD-L1 expression ≥ 50 % on TC or ≥ 10 % on IC, EGFR/ALK-negative, first-line;2021-06-01;2021-11-19;2021-11-19;No;No;Tecentriq as monotherapy is used in adult patients for the first-line treatment of metastatic non-small cell lung cancer (NSCLC) whose tumors have PD-L1 expression ≥ 50% of tumor cells (tumor cells, TC) or ≥ 10 % in tumor-infiltrating immune cells (IC) and who do not have EGFR (epidermal growth factor receptor) mutations or ALK (anaplastic lymphoma kinase)-positive NSCLC.;"a) Adults with metastatic non-small cell lung cancer (NSCLC) whose tumors have PD-L1 expression ≥ 50% of tumor cells and who do not have EGFR mutations or ALK-positive NSCLC; first line";3940.0;4430.0;4185.0;Pembrolizumab as monotherapy;No additional benefit;Roche Pharma AG;Valid;Valid;New application area;No;Oncology;No additional benefit;Overall Survival, Investigator-assessed PFS (RECIST v1.1), Investigator-assessed ORR (RECIST v1.1), Investigator-assessed DOR (RECIST v1.1), Investigator-assessed OS and PFS (RECIST v1.1) using SP263 IHC assay, OS rate at 1 and 2 years, Patient-reported outcomes (EORTC QLQ-C30 and EORTC QLQ-LC13), Adverse events, Immunogenicity, Investigator-assessed OS and PFS (RECIST v1.1) using 22C3 PD-L1 IHC assay, PFS rate at 6 months and 1 year, OS rate at 3 years, Subgroup analyses for investigator-assessed OS and PFS (RECIST v1.1), Health status assessed by EQ-5D-3L;"IMpower110:  
Phase III, randomized controlled trial, open, active-controlled, parallel, multicentric";2021-06-01-D-671;"IMpower110:  
Platinum-based chemotherapy"